JAID/JSC 感染症治療ガイドライン ―呼吸器感染症
Saved in:
| Published in | 感染症学雑誌 Vol. 88; no. 1; pp. 1 - 109 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | Japanese |
| Published |
一般社団法人 日本感染症学会
20.01.2014
|
| Online Access | Get full text |
| ISSN | 0387-5911 1884-569X |
| DOI | 10.11150/kansenshogakuzasshi.88.1 |
Cover
| Author | 三笠, 桂一 小林, 治 阿部, 修一 塚田, 弘樹 前田, 光一 坂田, 宏 中村（内山）, ふくみ 笠原, 敬 岸田, 直樹 吉田, 耕一郎 岩田, 敏 門田, 淳一 栁原, 克紀 青木, 洋介 青木, 信樹 関, 雅文 尾内, 一信 比嘉, 太 徳江, 豊 |
|---|---|
| Author_xml | – sequence: 1 fullname: 青木, 洋介 organization: 佐賀大学医学部国際医療学講座・臨床感染症学分野 – sequence: 1 fullname: 笠原, 敬 organization: 奈良県立医科大学感染症センター – sequence: 1 fullname: 阿部, 修一 organization: 山形大学医学部附属病院第一内科・検査部 – sequence: 1 fullname: 三笠, 桂一 organization: 奈良県立医科大学感染症センター – sequence: 1 fullname: 坂田, 宏 organization: 旭川厚生病院小児科 – sequence: 1 fullname: 徳江, 豊 organization: 群馬大学医学部附属病院感染制御部 – sequence: 1 fullname: 比嘉, 太 organization: 琉球大学医学部第一内科 – sequence: 1 fullname: 青木, 信樹 organization: 信楽園病院内科 – sequence: 1 fullname: 塚田, 弘樹 organization: 新潟市民病院感染症・呼吸器内科 – sequence: 1 fullname: 関, 雅文 organization: 大阪大学医学部附属病院感染制御部 – sequence: 1 fullname: 栁原, 克紀 organization: 長崎大学大学院医歯薬学総合研究科病態解析・診断学分野（臨床検査医学） – sequence: 1 fullname: 門田, 淳一 organization: 大分大学医学部呼吸器・感染症内科学講座 – sequence: 1 fullname: 中村（内山）, ふくみ organization: 奈良県立医科大学病原体・感染防御医学講座 – sequence: 1 fullname: 前田, 光一 organization: 奈良県立医科大学感染症センター – sequence: 1 fullname: 岩田, 敏 organization: 慶應義塾大学医学部感染制御センター – sequence: 1 fullname: 尾内, 一信 organization: 川崎医科大学小児科 – sequence: 1 fullname: 岸田, 直樹 organization: 手稲渓仁会病院総合内科・感染症科 – sequence: 1 fullname: 吉田, 耕一郎 organization: 近畿大学医学部附属病院安全管理部感染対策室 – sequence: 1 fullname: 小林, 治 organization: 杏林大学保健学部看護学科 |
| BookMark | eNptkL9Kw1AYxS9SwVr7DvUB0t7vJjf57map_1oLDiq4hZvkpk1bU8mtg07SCuKmiEinLg4KTroI-jSGpq8hWHVyOb8z_DjDWSa5uB8rQlaBlgGA00pXxlrFut1vye7JmdS6HZURy7BA8oBoGdwWhzmSpyY6BhcAS6SodeRRSoVFGWd5stao1tcrjb1aKbuYZJPb2f1l9vI-Gw_T4XM6fEhHV-no6bu8lj7P76Y3H9Prt-n48c9eIYuh7GlV_GGBHGxu7Ne2jebuVr1WbRodBlwapnBACI8pYLbwbW4jD8CnCoNAOAIpoJQWIKeh5bGQ2SEPBDIEZJ5PBYJZIDvz3Y4eyJZyj5PoSCanrkwGkd9T7j9XuIguzOPX8tsycTvS_ALxMnNO |
| ContentType | Journal Article |
| Copyright | 2014 一般社団法人 日本感染症学会 |
| Copyright_xml | – notice: 2014 一般社団法人 日本感染症学会 |
| DOI | 10.11150/kansenshogakuzasshi.88.1 |
| DeliveryMethod | fulltext_linktorsrc |
| EISSN | 1884-569X |
| EndPage | 109 |
| ExternalDocumentID | article_kansenshogakuzasshi_88_1_88_1_article_char_ja |
| GroupedDBID | ALMA_UNASSIGNED_HOLDINGS JSF KQ8 OK1 RJT SJN |
| ID | FETCH-LOGICAL-j215a-397199b2e1269c65685d1c0e8dd9798018aa41850f4b2f26f5d9828182bc09813 |
| ISSN | 0387-5911 |
| IngestDate | Wed Sep 03 06:30:33 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | false |
| IsScholarly | true |
| Issue | 1 |
| Language | Japanese |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-j215a-397199b2e1269c65685d1c0e8dd9798018aa41850f4b2f26f5d9828182bc09813 |
| OpenAccessLink | https://www.jstage.jst.go.jp/article/kansenshogakuzasshi/88/1/88_1/_article/-char/ja |
| PageCount | 109 |
| ParticipantIDs | jstage_primary_article_kansenshogakuzasshi_88_1_88_1_article_char_ja |
| PublicationCentury | 2000 |
| PublicationDate | 2014/01/20 |
| PublicationDateYYYYMMDD | 2014-01-20 |
| PublicationDate_xml | – month: 01 year: 2014 text: 2014/01/20 day: 20 |
| PublicationDecade | 2010 |
| PublicationTitle | 感染症学雑誌 |
| PublicationTitleAlternate | 感染症誌 |
| PublicationYear | 2014 |
| Publisher | 一般社団法人 日本感染症学会 |
| Publisher_xml | – name: 一般社団法人 日本感染症学会 |
| References | 104) von Baum H, Welte T, Marre R, Suttorp N, Ewig S, CAPNETZ study group. Community-acquired pneumonia through Enterobacteriaceae and Pseudomonas aeruginosa： Diagnosis, incidence and predictors. Eur Resp J. 2010；35：598―605 109) Baddour LM, Yu VL, Klugman KP, Feldman C, Ortqvist A, Rello J, et al. Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am j Respir Crit Care Med. 2004；170：440―4 185) Kotton CN, Kumar D,C aliendo AM, Asberg A, Chou S, Snydman DR, et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation. 2010；89(7)：779―95. 40) Kuo CC, Jackson LA, Lee A, Grayston JT. In vitro activities of azithromycin, clarithromycin, and other antibiotics against Chlamydia pneumoniae. Antimicrob Agents Chemother 1996；40：2669―70. 212) Foglia E, Meier MD, Elward A. Ventilator-associated pneumonia in neonatal and pediatric intensive care unit patients. Clin Microbiol Rev. 2007；20：409―25. 148) Ito I, Kadowaki S, Tanabe N, Haruna A, Kase M, Yasutomo Y, et al. Tazobactam/piperacillin for moderateto-severe pneumonia in patients with risk for aspiration： Comparison with imipenem/cilastatin. Pulm Pharmacol Ther. 2010；23：403―10 333) 山本正彦.：DPB に対するエリスロマイシンの治療効果―二重盲検による検討―．厚生省びまん性肺疾患調査研究班平成2 年度報告書．1991：p18―20. 15) 東山康仁，渡辺彰，青木信樹，二木芳人，河野茂：慢性閉塞性肺疾患症例の急性増悪に対するニューキノロン系抗菌薬とβ―ラクタム系抗菌薬の有用性．日化療会誌．2009；56（1）：33―48. 16) van der Heijden YF, Maruri F, Blackman A, Holt E, Warkentin JV, Shepherd BE, et al.：Fluoroquinolone exposure prior to tuberculosis diagnosis is associated with an increased risk of death. Int J Tuberc Lung Dis. 2012；16：1162―7. 51) American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005；171：388―416. 81) Kainer MA, Devasia RA, Jones TF, Simmons BP, Melton K, Chow S, et al. Response to emerging infection leading to outbreak ofl inezolid-resistant enterococci. Emerg Infect Dis. 2007；13：1024―30. 330) 工藤翔二，植竹健司，萩原弘一，平山雅清，許栄宏，木村仁，他.：びまん性汎細気管支炎にたいするエリスロマイシン少量長期投与の臨床効果に関する研究―4 年間の治療成績．日胸疾会誌．1987；25：632―42. 19) Martin-Loeches I, Lisboa T, Rodriguez, Putensen C, Annane D,Garnacho-Montero J, et al. Combination antibiotic therapy with macrorides improves survival in intubated patients with community-acquired pneumonia. Intensive Care Med. 2010；36(4)：612―20 387) South East Asia Innfectious Disease Clinical Research Network：Effect of double dose oseltamivir on clinical and virological outcomes in children and adults admitted to hospital with severe influenza：double blindrandomised controlled trial. BMJ 2013；346：f3039 126) 日本化学療法学会，日本嫌気性菌感染症研究会．嫌気性菌感染症診断・治療ガイドライン2007 協和企画， 東京，2007 46) Yamamoto N, Fujita J, Shinzato T, Higa F, Tateyama M, Tohyama M, et al.：In vitro activities of sitafloxacin compared with several fluoroquinolones against Streptococcus anginosus and Streptococcus constellatus. Int J Antimicrob Agents 2006；27：171―3. 374) Liston SL, Gehrz RC, Siegel LG, Tilelli J.：Bacterial tracheitis. Am J Dis Child. 1983；137：764―7. 409) Yoshikawa M, Koyama N, Hontsu S, Yamamoto Y, Mikasa K, Kimura H.：Lessons from eight cases of adult pulmonary toxocariasis： abridged republication. Respirology. 2011；16：1014―5. 136) 嚥下性肺疾患研究会．嚥下性肺疾患の診断と治療．ファイザー，東京，2003 366) Kabir AR, Mollah AH, Anwar KS, Rahman AK, Amin R, Rahman ME.：Management of bronchiolitis without antibiotics：a multicentre randomized control trial in Bangladesh. Acta Paediatr. 2009；98：1593―9. 242) Davies HE, Davies RJ, Davies CW. Management of pleural infection in adults：British Thoracic Society Pleural Disease Guideline 2010. Thorax. 2010；65 Suppl 2：ii41―53. 402) Rim HJ.：Paragonimiasis： experimental and clinical experience with praziquantel in Korea. Arzneimittelforschung. 1984；34：1197―203. 394) Streng A, Grote V, Liese JG.：Severe influenza cases in paediatric intensive care units in Germany during the pre-pandemic seasons 2005 to 2008. BMC Infect Dis. 2011；11：233. 266) Villarino ME, Ridzon R, Weismuller PC, Elcock M, Maxwell RM, Meador J, et al.： Rifampin preventive therapy for tuberculosis infection： experience with 157 adolescents. Am J Respir Crit Care Med. 1997；155：1735―8. 233) Civen R, Jousimies-Somer H, Marina M, Borenstein L, Shah H, Finegold SM. A retrospective review of cases of anaerobic empyema and update of bacteriology. Clin Infect Dis. 1995；20 Suppl 2：S224―9. 119) Hedlund J, Ortqvist A, Ahlqvist T, Augustinsson A, Beckman H, Blanck C, et al. Management of patients with community-acquired pneumonia treated in hospital in Sweden. Scand J Infect Dis. 2002：34(12),887―92 191) McIntosh K. Community-acquired pneumonia in children. N Engl J Med. 2002；346：429―3 392) Wieching A, Benser J, Kohlhauser-Vollmuth C, Weissbrich B, Streng A, Liese JG.：Clinical characteristics of pediatric hospitalizations associated with 2009 pandemic influenza A (H1N1) in Northern Bavaria, Germany. BMC Res Notes. 2012；5：304. 113) Finch R, Schürmann D, Collins O, Kubin R, McGivern J, Bobbaers H, et al. Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment. Antimicrob Agents Chemother 2002：46,1746―54 65) Koulent D, Rello J. Hospital-acquired pneumonia in the 21st century： a review of existing treatment options and their impact on patient care. Expert Opin Pharmacother 2006；7：1555―69 378) Taylor B, Abbott GD, Kerr MM, Fergusson DM.： Amoxycillin and co-trimoxazole in presumed viral respiratory infections of childhood：placebo-controlled trial. Br Med J. 1977；2(6086)：552―4. 390) Ameican Academy of Peiatrics. Haemophilus influenzae infections. In： Redbook. 29th ed. 2012,pp439―53. 135) The JRS Guidelines for the Management of hospital-acquired pneumonia in adults. The committee for the JRS guidelines in management of respiratory infections. 2008； Tokyo, Japan 日本呼吸器学会「呼吸器感染症に関するガイドライン作成委員会」．成人院内肺炎診療ガイドライン．日本呼吸器学会，東京，2008 291) 高松勇．特集予防接種BCG の新しい接種方式について―科学的根拠に基づく結核予防を求めて―．公衆衛生．2006；70： 266―70. 362) Shay DK, Holman RC, Newman RD, Liu LL, Stout JW, Anderson LJ.： Bronchiolitis-associated hospitalizations among US children, 1980―1996. JAMA. 1999；282：1440―6. 158) Karino F, Deguchi N, Kanda H, Ohe M, Kondo K, Tada M, et al. Evaluation of the efficacy and safety of biapenem against pneumonia in the elderly and a study on its pharmacokinetics. J Infect Chemother. 2013；19(1)：98―102 105) Seymann GB, Di Franceso L, Sharpe B, Rohde J, Fedullo P, Schneir A, et al. The HCAP gap： differences between self-reported practice patterns and published guidelines for health care-associated pneumonia. Clin Infect Dis. 2009；49：1868―74 139) Muder RR. Pneumonia in residents of long-term care facilities： epidemiology, management, and prevention. Am J Med. 1998；105： 319―30 215) Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer： 2010 update by The Infectious Diseases Society of America. Clin Infect Dis. 2011；52(4)：e56-e93. 10) Seki M, Watanabe A, Mikasa K, Kadota J, Kohno S. Revision of the severity rating and classification of hospital-acquired pneumonia in the Japanese Respiratory Society guidelines. Respirology 2008；13：880―5. 244) Chakrabarti B, Davies PD. Pleural tuberculosis. Monaldi Arch Chest Dis. 2006；65：26―33. 393) Gutierrez C, Nazar GA, Torres JP.：Otolaryngological complications in patients infected with the influenza A (H1N1) virus. Otolaryngol Head Neck Surg. 2012；146：478―82. 156) Brtlett JG. Aspiration pneumonia in adults. Uptodate, version 16.2 2008 115) Vergis EN, Indorf A, File TM Jr, Phillips J, Bates J, Tan J, et al. Azithromycin vs cefuroxime plus erythromycin for empirical treatment of community-acquired pneumonia in hospitalized patients： a prospective, randomized, multicenter trial. Arch Intern Med. 2000；160(9)：1294―300 225) Katayama Y, Minami H, Enomoto M, Takano T, Hayashi S, Lee YK. Usefulness of Gram staining of tracheal aspirates in initial therapy for ventilator-associated pneumonia in extremely preterm neonates. J Perinatol. 2010；30：270―4. 371) Wong VK, Mason WH.：Branhamella catarrhalis as a cause of bacterial tracheitis. Pediatr Infect Dis J. 1987； 6：945―6. 186) Asberg A, Humar A, Rollag H, Jardine AG, Mouras H, Pescovitz MD, et al. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant. 2007；7：2106―13. 341) 白井亮，阿部航，良永倫子，石松祐二，松原祐一，川上かおる，他.：びまん性汎細気管支炎に対するエリスロマイシン療法の中止可能症例の検討―投与中止例と投与継続例の比較―．感染症誌．1997；71：1155―61. 124) Livemore DM, Mushtaq S, Warner M. Selectivity of ertapnem for Psudomonas aeruginosa mutants cross-resisitant to other carbapenems. J Antimicrob Chemother. 2005；55(3)： |
| References_xml | – reference: 303) Morozumi M, Iwata S, Hasegawa K, Chiba N, Takayanagi R, Matsubara K, et al.：Increased macrolide resistance of Mycoplasma pneumoniae in pediatric patients with community-acquired pneumonia. Antimicrob Agents Chemother. 2008；52：348―50. – reference: 345) 小林宏行，武田博明，酒寄亨，川上義和，大塚義紀，田村昌士，他.：びまん性汎細気管支炎に対する azithromycin の臨床的検討．感染症誌．1995；69：711―22. – reference: 113) Finch R, Schürmann D, Collins O, Kubin R, McGivern J, Bobbaers H, et al. Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment. Antimicrob Agents Chemother 2002：46,1746―54 – reference: 209) 生方公子，諸角美由紀，岩田敏．小児におけるマクロライド高度耐性・肺炎マイコプラズマの大流行．IASR 2011；32：337―9. – reference: 16) van der Heijden YF, Maruri F, Blackman A, Holt E, Warkentin JV, Shepherd BE, et al.：Fluoroquinolone exposure prior to tuberculosis diagnosis is associated with an increased risk of death. Int J Tuberc Lung Dis. 2012；16：1162―7. – reference: 7) García-Vázquez E, Marcos MA, Mensa J, de Roux A, Puig J, Font C , et al. Assessment of the usefulness of sputum culture for diagnosis of community-acquired pneumonia using the PORT predictive scoring system. Arch Intern Med. 2004；164：1807―11. – reference: 291) 高松勇．特集予防接種BCG の新しい接種方式について―科学的根拠に基づく結核予防を求めて―．公衆衛生．2006；70： 266―70. – reference: 107) Asadi L, Sligl WI, Eurich DT, Colmers IN, Tjosvold L, Marrie TJ, et al. Macroride-based regimens and mortality in hospitalized patients with community-acquired pneumonia：A systematic review and meta-analysis. Clin Infect Dis. 2012；55(3)：371―80 – reference: 332) Nagai H, Shishido H, Yoneda R, Yamaguchi E, Tamura A, Kurashima A.： Long-term low-dose administration of erythromycin to patients with diffuse panbronchiolitis. Respiration. 1991；58：145―9. – reference: 247) 小児呼吸器感染症診療ガイドライン作成委員会．主な予防接種対象疾患 5．結核．小児呼吸器感染症診療ガイドライン2011 協和企画，東京，2011；p84―88 – reference: 44) Barnham M, Weightman N, Anderson A, Pagan F, Chapman S. Review of 17 cases of pneumonia caused by Streptococcus pyogenes. Eur J Clin Microbiol Infect Dis 1999；18：506―509. – reference: 149) El-Solh AA, Pietrantoni C, Bhat A, Bhora M, Berbary E. Indicators of potentially drug-resistant bacteria in severe nursing home-acquired pneumonia. Clin Infect Dis. 2004；39(4)：474―80 – reference: 232) Brook I, Frazier EH. Aerobic and anaerobic microbiology of empyema. A retrospective review in two military hospitals. Chest. 1993；103：1502―7. – reference: 379) O’Brien KL, Dowell SF, Schwartz B, Marcy SM, Phillips WR, Gerber MA.：Cough illness/Bronchitis―Principles of judicious use of antimicrobial agents. Pediatrics 1998；101(suppl 1)：178―181. – reference: 43) Shinzato T, Saito A.：The Streptococcus milleri group as a cause of pulmonary infections. Clin Inf Dis 1995；21 Suppl3：S238―43. – reference: 231) Light RW. Parapneumonic effusions and empyema. Proc Am Thorac Soc. 2006；3：75―80. – reference: 110) Pallares R, Gudior F, Liñares J, Ariza J, Rufi G, Murgui L, et al. Risk factors and response to antibiotic therapy in adults with bacteremic pneumonia caused by penicillin-resistant pneumococci. N Engl J Med. 1987；317：18―22 – reference: 100) Carratalà J, Mykietiuk A, Fernández-Sabé N, Suárez C, Dorca J, Verdaguer R, et al. Healthcare-associated pneumonia requiring hospital admission：epidemiology, antibiotic therapy, and clinical outcomes. Arch Intern Med. 2007；167(13)：1393―9 – reference: 165) Greene RE, Schlamm HT, Oestmann JW, Stark P, Durand C, Lortholary O, et al. Imaging findings in acute invasive pulmonary aspergillosis： clinical significance of the halo sign. Clin Infect Dis. 2007；44(3)：373―9. – reference: 249) East African/British Medical Research Councils.： Controlled clinical trial of four short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Third report. Lancet. 1974；2：237―40. – reference: 274) Griffith DE, Brown BA, Girard WM, Murphy DT, Wallace RJ Jr.：Azithromycin activity against Mycobacterium avium complex lung disease in patients who were not infected with human immunodeficiency virus. Clin Infect Dis. 1996；23：983―9. – reference: 377) Gordon M, Lovell S, Dugdale AE.：The value of antibiotics in minor respiratory illness in children. A controlled trial. Med J Aust. 1974；1：304―6. – reference: 133) Walkey AJ, Wiener RS. Macrolide antibiotics and survival in patients with acute lung injury. Chest. 2012；141(5)；1153―9 – reference: 139) Muder RR. Pneumonia in residents of long-term care facilities： epidemiology, management, and prevention. Am J Med. 1998；105： 319―30 – reference: 167) Cornely OA, Maertens J, Bresnik M, Ebrahimi R, Ullmann AJ, Bouza E, et al. Liposomal amphotericin B as initial therapy for invasive mold infection： a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoadtrial). Clin Infect Dis. 2007；44(10)：1289―97. – reference: 353) Cherry JD. Croup (laryngitis, laryngotracheitis, spasmodic croup, laryngotracheobronchitis, bacterial tracheitis). In： Feigin RD, Cherry J, Demmler-Harrison GJ, Kaplan SL, ed. Feigin and Cherry’s Textbook of Pediatric Infectious Diseases, 6th ed. Saunders, Philadelphia, 2009,pp254―68. – reference: 407) Smith H, Holland C, Taylor M, Magnaval JF, Schants P, Maizels R.：How common is human toxo-cariasis? Towards standardizing our knowledge. Trends Parasitol. 2009；25：182―8. – reference: 117) Yanagihara K, Izumikawa K, Higa F, Tateyama M, Tokimatsu I, Hiramatsu K, et al. Efficacy of azithromycin in the treatment of community-acquired pneumonia, including patients with macrolide-resistant Streptococcus pneumoniae infection. Intern Med. 2009；48(7)：527―35 – reference: 266) Villarino ME, Ridzon R, Weismuller PC, Elcock M, Maxwell RM, Meador J, et al.： Rifampin preventive therapy for tuberculosis infection： experience with 157 adolescents. Am J Respir Crit Care Med. 1997；155：1735―8. – reference: 283) Sauret J, Hernández-Flix S, Castro E, Hernández L, Ausina V, Coll P.：Treatment of pulmonary disease caused by Mycobacterium kansasii： results of 18 vs 12 months’ chemotherapy. Tuber Lung Dis. 1995；76：104―8. – reference: 88) Cunha BA： Oral antibiotic therapy of serious systemic infections. Med Clin N Am 2006；90：1197―222. – reference: 102) Craven DE. What is health-care associated pneumonia, and how should it be treated? Curr Opin Infect Dis. 2006；19：153―60 – reference: 371) Wong VK, Mason WH.：Branhamella catarrhalis as a cause of bacterial tracheitis. Pediatr Infect Dis J. 1987； 6：945―6. – reference: 288) Jeon K, Kwon OJ, Lee NY, Kim BJ, Kook YH, Lee SH, et al.：Antibiotic treatment of Mycobacterium abscessus lung disease： a retrospective analysis of 65 patients. Am J Respir Crit Care Med. 2009；180：896―902. – reference: 69) 公益社団法人日本化学療法学会抗菌薬TDMガイドライン作成委員会．抗菌薬TDM ガイドラインhttp://www.chemotherapy.or.jp/guideline/tdm_executive-summary.pdf – reference: 390) Ameican Academy of Peiatrics. Haemophilus influenzae infections. In： Redbook. 29th ed. 2012,pp439―53. – reference: 148) Ito I, Kadowaki S, Tanabe N, Haruna A, Kase M, Yasutomo Y, et al. Tazobactam/piperacillin for moderateto-severe pneumonia in patients with risk for aspiration： Comparison with imipenem/cilastatin. Pulm Pharmacol Ther. 2010；23：403―10 – reference: 326) Anzueto A, Bishai WR, Pottumarthy S.： Role of oral extended-spectrum cephems in the treatment of acute exacerbation of chronic bronchitis. Diagn Microbiol Infect Dis. 2007；57(Suppl 3)：31S―8S. – reference: 267) Menzies D, Long R, Trajman A, Dion MJ, Yang J, AlJahdali H, et al.：Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection： a randomized trial. Ann Intern Med. 2008；149：689―97. – reference: 173) Caillot D, Thiébaut A, Herbrecht R, de Botton S, Pigneux A, Bernard F, et al. Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies： a randomized pilot study (Combistrat trial). Cancer. 2007；110(12)：2740―6. – reference: 342) Kadota J, Mukae H, Ishii H, Nagata T, Kaida H.： Long-term efficacy and safety of clarithromycin treatment in patients with diffuse panbronchiolitis. Respir Med. 2003；97：844―50. – reference: 146) El-Solh AA, Pietrantoni C, Bhat A, Aquilina AT, Okada M, Grover V, et al. Microbiology of severe aspilation pneumonia in institutionalized elderly. Am J Respir Crit Care Med. 2003；167(12)：1650―4 – reference: 29) Niki Y, Hanaki H, Matsumoto T, Yagisawa M, Kohno S, Aoki N, et al. Nationwide surveillance of bacterial respiratory pathogens condected by Japanese Society of Chemotherapy in 2008：general view of the pathogens’ antibacterial susceptibility. J Infect Chemother 2011；17(4)：510―523. – reference: 217) 黒木春郎，石川信泰，星岡 明，下条直樹，河野陽一，上原すゞ子，他．小児科領域におけるマクロライド系薬剤長期療法の経験．日小会誌．1996；100：1194―201. – reference: 397) Nakamura-Uchiyama F, Nawa Y.：Paragonimiasis. In：Tropical Lung Disease 2nd Edition, OP Sharma ed., Taylor and Francis, NY. 2006, pp295―326. – reference: 151) 白石貴寿，坂本晃世，岩武資善，中村泰士，横山博.：誤嚥性肺炎に対する抗菌薬治療の現状調査について． 日病薬師会誌． 2009；45：1501―4 – reference: 270) Tanaka E, Kimoto T, Tsuyuguchi K, Watanabe I, Matsumoto H, Niimi A, et al.：Effect of clarithromycin regimen for Mycobacterium avium complex pulmonary disease. Am J Respir Crit Care Med. 1999；160：866―72. – reference: 229) 佐藤吉壮．迷わない! 重症感染症への抗菌薬・抗ウイルス薬III．各種感染症・病態における診断の決め手と治療薬の選びかた 新生児の感染症．小児科診療．2010；73：2035―41. – reference: 391) Jordan WS Jr, Denny FW Jr, Badger GF, Curtiss C, Dingle JH, Oseasohn R, et al.：A study of illnessin a group of Cleveland families. XVII. The occurrence of Asian influenza. Am J Hyg 1958；68：190―212. – reference: 204) 黒崎知道，太田文夫，玉井和人，星岡明，高橋良仁，小俣卓，他．H. influenzaeのampicillin感受性の年次別推移とampicillinに対する最小発育阻止濃度（MIC）2μg/ml のH. influenzaeによる気管支肺感染症のペニシリン系抗菌薬の治療効果について．日小呼誌．2001；12：18―23. – reference: 404) Asato R, Nakasone T, Yoshida C, Arakaki T, Ikeshiro T, Murakami H, et al.：Current status of Strongyloides infection in Okinawa, Japan. Jpn J Trop Med Hyg 1992；20：169―73. – reference: 127) Yamamoto Y, Izumikawa K, Morinaga Y, Nakamura S, Kurihara S, Imamura Y, et al. Prospective randomized comparison study of piperacillin/tazobactam and meropenem for healthcare-associated pneumonia in Japan. J Infect Chemother. 2013；19(2)：291―8 – reference: 220) 坂田宏．特集 呼吸器感染のそこが知りたい 新生児の肺炎．小児内科．2004；36：104―7. – reference: 244) Chakrabarti B, Davies PD. Pleural tuberculosis. Monaldi Arch Chest Dis. 2006；65：26―33. – reference: 297) Gonzales R, Bartlett JG, Besser RE, Cooper RJ, Hickner JM, Hoffman JR, et al.： Principles of appropriate antibiotic use for treatment of uncomplicated acute bronchitis： background. Ann Intern Med. 2001；134：521―9. – reference: 80) Kohno S, Yamaguchi K, Aikawa N, Sumiyama Y, Odagiri S, Aoki N, et al. Linezolid versus vancomycin for the treatment of infections caused by methicillin-resistant Staphylococcus aureus in Japan. J Antimicrob Chemother 2007；60：1361―9. – reference: 95) Clinical Laboratory Standards Institute：Performance standards for Antimicrobial susceptibility testing； twentieth informational supplement. M100-S20. Clinical and Laboratory Standards Institute, Wayne PA, 2010. – reference: 85) Wunderink RG, Rello J, Cammarata SK, Croos-Dabrera RV, Kollef MH： Linezolid vs vancomycin： analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003；124：1789―97. – reference: 31) Morozumi M,Takahasi T, Ubukata K. Macrolide-resistant Mycoplasma pneumoniae：characteristics of isolates and clinical aspects of community-acquired pneumonia. J Infect Chemother 2010；16：78―86. – reference: 37) Griffin AT, Payrani P, Wiemken T, Arnold F. Macrolides versus quinolones in Legionella pneumonia：results from the community-aquired pneumonia organization international study. Int J Tuberc Lung Dis 2010；14：495―499 – reference: 370) Jones R, Santos JI, Overall JC Jr.：Bacterial tracheitis. JAMA. 1979；242：721―6. – reference: 68) Rotstein C, Evans G, Born A, Grossman R, Light RB, Magder S, et al. Clinical practice guidelines for hospital-acquired pneumonia and ventilator-associated pneumonia in adults. Can J Infect Dis Med Microbiol. 2008；19：19―53. – reference: 277) Kobashi Y, Matsushima T, Oka M.： A double-blind randomized study of aminoglycoside infusion with combined therapy for pulmonary Mycobacterium avium complex disease. Respir Med. 2007；101：130―8. – reference: 112) Loeb M, Carusone SC, Goeree R, Walter SD, Brazil K, Krueger P, et al. Effect of a clinical pathway to reduce hospitalizations in nursing home residents with pneumonia： a randomized controlled trial. JAMA. 2006；295：2503―10 – reference: 179) Pappas PG, Perfect JR, Cloud GA, Larsen RA, Pankey GA, Lancaster DJ, et al. Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy. Clin Infect Dis. 2001；33(5)：690―9. – reference: 103) El Solh AA, Pietrantoni C, Bhat A, Bhora M, Berbary E. Indicators of potentially drug-resistant bacteria in severe nursing home acquired pneumonia. Clin Infect Dis. 2004；39：474―80 – reference: 132) Waterer GW, Rello J, Wunderink RG. Management of community-acqired pneumonia. Am J Respir Crit Care Med. 2011；183(2)； 157―64 – reference: 268) The Resarch Committee of the British Thoracic Society：Pulmonary disease caused by Mycobacterium aviumintracellulare in HIV-negative patients： five-year follow-up of patients receiving standardised treatment. Int J Tuberc Lung Dis. 2002；6： 628―34. – reference: 35) Akaike H, Miyashita N, Kubo M, Kawai Y, Tanaka T, Ogita S,et al.：In vitro activities of 11 antimicrobial agents against macrolide-resistant Mycoplasma pneumoniae isolates from pediatric patients： Results from a multicenter surveillance study. Jpn J Infect Dis 2012；65：535―538. – reference: 376) Smucny J, Fahey T, Becker L, Glazier R.：Antibiotics for acute bronchitis. Cochrane Database Syst Rev. 2004；(4)：CD000245. – reference: 6) Gleckman R, DeVita J, Hibert D, Pelletier C, Martin R. Sputum gram stain assessment in community-acquired bacteremic pneumonia. J Clin Microbiol. 1988；26：846―9. – reference: 373) Bernstein T, Brilli R, Jacobs B.：Is bacterial tracheitis changing? A 14-month experience in apediatric intensive care unit. Clin Infect Dis. 1998；27：458―62. – reference: 109) Baddour LM, Yu VL, Klugman KP, Feldman C, Ortqvist A, Rello J, et al. Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am j Respir Crit Care Med. 2004；170：440―4 – reference: 185) Kotton CN, Kumar D,C aliendo AM, Asberg A, Chou S, Snydman DR, et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation. 2010；89(7)：779―95. – reference: 156) Brtlett JG. Aspiration pneumonia in adults. Uptodate, version 16.2 2008 – reference: 347) Serisier DJ, Martin ML, McGuckin MA, Lourie R, Chen AC, Brain B, et al.： Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis： the BLESS randomized controlled trial. JAMA. 2013；309：1260―7. – reference: 125) Tsukada H, Sakai K, Cho H, Kimura Y, Tetsuka T, Nakajima H, et al. Retrospective investigation of the clinical effects of tazobactam/piperacillin and sulbactam/ampicillin on aspiration pneumonia caused by Klebsiella pneumoniae. J Infect Chemother. 2012；18(5)：715―21 – reference: 402) Rim HJ.：Paragonimiasis： experimental and clinical experience with praziquantel in Korea. Arzneimittelforschung. 1984；34：1197―203. – reference: 223) Couto RC, Carvalho EA, Pedrosa TM, Pedroso ER, Neto MC, Biscione FM. A 10-year prospective surveillance of nosocomial infections in neonatal intensive care units. Am J Infect Control. 2007；35：183―9. – reference: 255) 日本結核病学会（編）．結核診療ガイドライン．改訂第2版：南江堂，東京，2012. – reference: 273) Griffith DE,Brown-Elliott BA, Langsjoen B, Zhang Y, Pan X, Girard W, et al.：Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease. Am J Respir Crit Care Med. 2006；174：928―34. – reference: 182) Thomas CF Jr, Limper AH. Pneumocystis pneumonia. N Engl J Med. 2004；350(24)：2487―98. – reference: 202) Morozumi M, Takahashi T, Ubukata K. Macrolide-resistant Mycoplasma pneumoniae： characteristics of isolates and clinical aspects of community-acquired pneumonia. J Infect Chemother. 2010；16：78―86. – reference: 218) 宍戸春美．難治性呼吸器感染症．ヴァンメディカル．東京，1995：57―60. – reference: 134) Mrik PE. Aspiration pneumonitis and aspiration pneumonia. N Engl J Med 2001；344(9)：665―71 – reference: 22) Goto H, Shimada K, Ikemoto H, Oguri T, the Study group on antimicrobial susceptibility of pathogens isolated from respiratory infections. Antimicrobial susceptibility of pathogens isolated from more than 10000 patients with infectious respiratory diseases： a 25-year longitudinal study. J Infect Chemother 2009,15：347―60. – reference: 281) Pezzia W, Raleigh JW, Bailey MC, Toth EA, Silverblatt J.： Treatment of pulmonary disease due to Mycobacterium kansasii： recent experience with rifampin. Rev Infect Dis. 1981；3：1035―9. – reference: 32) Miyashita N, Kawai Y, Akaike H, Ouchi K, Hayashi T, Kurihara T, et al. Macrolide-resistant Mycoplasma pneumoniae in adolescents with community-acquired pneumonia. BMC Infect Dis 2012；12：126.doi：10.1186/1471-2334-12-126 – reference: 250) Hong Kong Chest Service/British Medical Research Council.： Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide. Results at 30 months. Am Rev Respir Dis. 1991；143：700―6. – reference: 105) Seymann GB, Di Franceso L, Sharpe B, Rohde J, Fedullo P, Schneir A, et al. The HCAP gap： differences between self-reported practice patterns and published guidelines for health care-associated pneumonia. Clin Infect Dis. 2009；49：1868―74 – reference: 228) 佐藤吉壮．新生児医療・必修基礎知識V．管理法 抗菌薬の使いかた．小児科診療．2010；73：1577―84. – reference: 339) Kadota J, Mukae H, Tomono K, Kohno S, Nasu M.： Efficacy of lomg-term macrolide antibiotic therapy in patients with diffuse panbronchiolitis： comparison between HLA-B54-positive and negative cases. Int J Antimicrob Agents. 2004；24：550―4. – reference: 239) Thys JP, Serruys-Schoutens E, Rocmans P, Herchuelz A, Vanderlinden MP, Yourassowsky E. Amikacin concentrations in uninfected postthoracotomy pleural fluid and in serum after intravenous and intrapleural injection. Chest. 1984；85：502―5. – reference: 57) Chastre J, Wolff M, Fagon JY, Chevret S, Thomas F, Wermert D, et al： Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults： a randomized trial. JAMA 2003；290：2588―98. – reference: 252) Ormerod LP, Horsfield N.： Short-course antituberculous chemotherapy for pulmonary and pleural disease： 5 years’ experience in clinical practice. Br J Dis Chest. 1987；81：268―71. – reference: 108) Vardakas KZ, Siempos II, Grammatikos A, Athanassa Z, Korbila IP, Falagas ME. Respiratory fluoroquinolones for the treatment of community-acquired pneumonia： a meta-analysis of randomized controlled trials. CMAJ. 2008；179(12)：1269―77 – reference: 5) Kohno S, Seki M, Watanabe A；CAP Study Group. Evaluation of an assessment system for the JRS 2005：A-DROP for the management of CAP in adults. Intern Med. 2011；50：1183―9. – reference: 219) Gallin JI, Alling DW, Malech HL, Wesley R, Koziol D, Marciano B, et al. Itraconazole to prevent fungal infections in chronic granulomatous disease. N Engl J Med. 2003；348：2416―22. – reference: 211) 小児呼吸器感染症診療ガイドライン作成委員会，日本小児科学会予防接種・感染症対策委員会．小児肺炎マイコプラズマ肺炎の診断と治療に関する小児呼吸器感染症診療ガイドライン 2011 追補版 2013 – reference: 308) Miravitlles M, Anzueto A, Ewig S, Legnani D, Stauch K.： Characterisation of exacerbations of chronic bronchitis and COPD in Europe： the GIANT study. Ther Adv Respir Dis. 2009 3(6)：267―77 – reference: 200) Sato Y, Toyonaga Y, Hanaki H, Nonoyama M, Oishi T, Sunakawa K. Nationwide survey of the development of drug-resistant pathogens in the pediatric field： drug sensitivity of Streptococcus pneumoniae in Japan. J Infect Chemother. 2009；15： 396―401. – reference: 34) Hoshino K, Inoue K, Murakami Y, Kurosaka Y, Namba K, Kashimoto Y, et al. In vitro and in vivo antibacterial activities of DC-159a, a new fluoroquinolone. Antimicrob Agents Chemother 2008；52：65―76. – reference: 412) Boggild AK, Keystone JS, Kain KC.：Tropical pulmonary eosinophilia： a case series in a setting of nonendemicity. Clin Infect Dis. 2004；39：1123―8. – reference: 362) Shay DK, Holman RC, Newman RD, Liu LL, Stout JW, Anderson LJ.： Bronchiolitis-associated hospitalizations among US children, 1980―1996. JAMA. 1999；282：1440―6. – reference: 388) Wright PF. Influenza viruses. In： Kliegman RM, Behrman RE, Jenson HB, Stanton BF, eds. Nelson Textbook of Pediatrics, 19th ed. Saunders, Philadelphia, 2011,pp1121―5. – reference: 184) Hughes W, Leoung G, Kramer F, Bozzette SA, Safrin S, Frame P, et al.：Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS. N Engl J Med. 1993；328：1521―7. – reference: 312) 河野茂，渡辺彰，青木信樹，二木芳人，門田淳一，藤田次郎，他：呼吸器感染症に対するlevofloxacin 500mg1日1回投与の臨床効果．日化療会誌．2009；57（S-2）：20―33. – reference: 187) Moretti S, Zikos P, VanLint MT, Tedone E, Occhini D, Gualandi F, et al. Forscarnet vs ganciclovir for cytomegalovirus (CMV) antigenemia after allogeneic hemopoietic stem cell transplantation (HSCT)： a randomised study. Bone Marrow Transplant. 1998； 22(2)：175―80. – reference: 403) Kunst H, Mack D, Kon OM, Banerjee AK, Chiodini P, Grant A.：Parasitic infections of the lung： a guide for the respiratory physician. Thorax. 2011；66：528―36. – reference: 73) Hull MW,Chow AW： Indigenous microflora and innate immunity of the head and neck. Infect Dis Clin N Am. 2007；21：265―82. – reference: 305) 日本呼吸器学会呼吸器感染症に関するガイドライン作成委員会：呼吸器感染症に関するガイドライン成人気道感染症診療の基本的考え方，日本呼吸器学会，東京，2003. – reference: 60) Kett DH, Cano E, Quartin AA, Mangino JE, Zervos MJ, Peyrani P, et al. Implementation of guidelines for management of possible multidrug-resistant pneumonia in intensive care： an observational, multicentre cohort study. Lancet Infect Dis. 2011；11(3)：181―9 – reference: 65) Koulent D, Rello J. Hospital-acquired pneumonia in the 21st century： a review of existing treatment options and their impact on patient care. Expert Opin Pharmacother 2006；7：1555―69 – reference: 354) Denny FW, Murphy TF, Clyde WA Jr, Collier AM, Henderson FW.： Croup：an 11-year study in a pediatric practice. Pediatrics 1983；71：871―6. – reference: 116) Contopoulos-Ioannidis DG, Ioannidis JP, Chew P, Lau J.Meta-analysis of randomized controlled trials on the comparative efficacy and safety of azithromycin against other antibiotics for lower respiratory tract infections. J Antimicrob Chemother. 2001；48(5)：691―703 – reference: 12) 日本呼吸器学会 呼吸感染症に関するガイドライン作成委員会 成人院内肺炎診療ガイドライン2007．日本呼吸器学会 – reference: 144) Gilbert DN, Moellering RC Jr, Eliopoulos GM, Chambers HF, Saag MS.eds.：The Sanford Guide to Antimicrobial Therapy 2011 41st Edition. Antimicrobial Therapy Inc. VA, USA 2011 – reference: 230) Colice GL, Curtis A, Deslauriers J, Heffner J, Light R, Littenberg B,et al. Medical and surgical treatment of parapneumonic effusions：an evidence-based guideline. Chest. 2000；118：1158―71. – reference: 19) Martin-Loeches I, Lisboa T, Rodriguez, Putensen C, Annane D,Garnacho-Montero J, et al. Combination antibiotic therapy with macrorides improves survival in intubated patients with community-acquired pneumonia. Intensive Care Med. 2010；36(4)：612―20 – reference: 251) British Thoracic Society.：A controlled trial of 6 months’ chemotherapy in pulmonary tuberculosis. Final report：results during the 36 months after the end of chemotherapy and beyond. Br J Dis Chest. 1984；78：330―6. – reference: 348) Altenburg J, de Graaff CS, Stienstra Y, Sloos JH, van Haren EHJ, Koppers RJH, et al.： Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis： the BAT randomized controlled trial. JAMA. 2013；309：1251―9. – reference: 262) Jasmer RM, Nahid P, Hopewell PC.：Clinical practice. Latent tuberculosis infection. N Engl J Med. 2002；347：1860―6. – reference: 340) Kadota J, Mukae H, Mizunoe S, Kishi K, Tokimatsu I, Nagai H, et al.： Long-term macrolide antibiotic therapy in the treatment of chronic small airway disease clinically mimicking diffuse panbronchiolitis. Intern Med. 2005；44：200―6. – reference: 76) Jacoby G, Bush K.β-lactam resistance in the 21st century. In： White DG, Alekshun MN, McDermott PF ed. Frontiers in Antimicrobial Resistance： a tribute to Stuart B. Levy. ASM Press, Washington DC, 2005, p299―313. – reference: 150) Wang JL, Chen KY, Fang CT, Hsueh PR, Yang PC, Chang SC. Changing bacteriology of adult community acquired lung abscess in Taiwan： Klebsiella pneumoniae versus anaerobes. Clin Infect Dis. 2005；40：915―22 – reference: 233) Civen R, Jousimies-Somer H, Marina M, Borenstein L, Shah H, Finegold SM. A retrospective review of cases of anaerobic empyema and update of bacteriology. Clin Infect Dis. 1995；20 Suppl 2：S224―9. – reference: 190) 中村明．気管支肺感染症病因診断の問題点―EMBの時代を迎えて．日本小児科学会雑誌．2003；107：1067―73. – reference: 380) Centers of Disease Prevention (CDC)：High levels of adamantane resistance among A (H3N2) viruses and interim guidelines for use of anti-viral agents--United States, 2005―06 influenza season. MMWR Morb Mortal Wkly Rep 2006；55(2)：44―6 – reference: 237) Hughes CE, Van Scoy RE. Antibiotic therapy of pleural empyema. Semin Respir Infect 1991；6：94―102. – reference: 206) 大嶋寛子，黒崎知道，太田文夫，玉井和人，上原すゞ子，新美仁男．Moraxella catarrhalisによる小児下気道感染症の臨床的検討（第1 報）．日児誌．1998；102：23―8. – reference: 311) Hui DS, Ip M, Ling T, Chang SC, Liao CH, Yoo C G, et al. A multicentre surveillance study on the characteristics, bacterial aetiologies and in vitro antibiotic susceptibilities in patients with acute exacerbations of chronic bronchitis. Respirology. 2011；16(3)：532―9. – reference: 163) Craven DE, Chroneou A, Zias N, Hjalmarson KI. Ventilator-associated tracheobronchitis： the impact of targeted antibiotic therapy on patient outcomes. Chest. 2009；135(2)：521―8 – reference: 265) Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council.： A double-blind placebo-controlledc linicaltrial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Am Rev Respir Dis. 1992；145：36―41. – reference: 17) Arnold FW, Summersgill JT, Lajoie AS, Peyrani P, Marrie TJ, Rossi P, et al. A Worldwide Perspective of Atypical Pathogens in Community-acquired Pneumonia. Am J Respir Crit Care Med. 2007；175：1086―93. – reference: 193) World Health Organization： Programme for the control of acute respiratory infections： technical bases for the WHO recommendations on the management of pneumonia in children at first-level health facilities. WHO/ARI/91.20. – reference: 208) Mogi A, Nishi J, Yoshinaga M, Harada H, Narahara S, Kawakami K, et al. Increased prevalence of penicillin-resistant viridans group streptococci in Japanese children with upperre spiratory infection treated by betalactam agents and in those with oncohematologic diseases. Pediatr Infect DisJ. 1997；16：1140―4. – reference: 40) Kuo CC, Jackson LA, Lee A, Grayston JT. In vitro activities of azithromycin, clarithromycin, and other antibiotics against Chlamydia pneumoniae. Antimicrob Agents Chemother 1996；40：2669―70. – reference: 271) Dautzenberg B, Piperno D, Diot P,Truffot-Pernot C, Chauvin JP.：Clarithromycin in the treatment of Mycobacterium avium lung infections in patients without AIDS. Clarithromycin Study Group of France. Chest. 1995；107：1035―40. – reference: 39) Muder RR, Yu VL.：Infection due to Legionella species other than L. pneumophila. Clin Infect Dis 2002；35：990―8. – reference: 189) 小児呼吸器感染症診療ガイドライン作成委員会．肺炎．小児呼吸器感染症診療ガイドライン2011 協和企画， 東京，2011； p29―49 – reference: 254) Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America： treatment of tuberculosis. Am J Respir Crit Care Med. 2003；167：603―62. – reference: 25) Weinstein MP, Klugman KP, Jones RN.：Rationale for revised penicillin susceptibility breakpoints versus Streptococcus pneumoniae：Coping with antimicrobial susceptibility in an era of resistance. Clin Infect Dis 2009,48：1596―600 – reference: 59) Venditti M, Falcone M, Corrao S, Licata G, Serra P； Study Group of the Italian Society of Internal Medicine.：Outcomes of patients hospitalized with community-acquired, health care-associated and hospital-acquired pneumonia. Ann Intern Med 2009；150：19―26. – reference: 294) 倉島篤行．新しい非結核性抗酸菌症の診断基準と治療対策．結核．2010；85：87―93. – reference: 36) Blázquez Garrido RM, Espinosa Parra FJ, Alemany Francés L, Ramos Guevara RM, Sánchez-Nieto JM, Segovia Hernández M. et al. Antimicrobial chemotherapy for Legionnaires disease： levofloxacin versus macrolides. Clin Infec Dis 2005；40：800―6. – reference: 45) Wajima T, Maruyama SY, Sunaoshi K, Nakayama E, Sunakawa K, Ubukata K. Distribution of emm type and antibiotic susceptibility of group A streptococci causing invasive and noninvasive diseases. J Med Microbiol 2008；57：1383―8. – reference: 194) Turner RB, Lande AE, Chase P, Hilton N, Weinberg D. Pneumonia in pediatric outpatients： cause and clinical manifestations. J Pediatr. 1987；111：194―200. – reference: 53) Watanabe A, Yanagihara K, Kohno S, Matsushima T；HAP study group： Multicenter survey on hospital-acquired pneumonia and the clinical efficacy of first-line antibiotics in Japan. Intern Med 2008；47：245―54. – reference: 114) Torres A, Garau J, Arvis P, Carlet J, Choudhri S, Kureishi A, et al. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia： the MOTIV study―a randomized clinical trial. Clin Infect Dis 2008；46(10)：1499―509 – reference: 319) Miravitlles M, Kruesmann F, Haverstock D, Perroncel R, Choudhri SH, Arvis P.： Sputum colour and bacteria in chronic bronchitis exacerbations： a pooled analysis. Eur Respir J. 2012；39(6)：1354―60. – reference: 164) Nseir S, Favory R, Jozefowicz E, Decamps F, Dewavrin F, Brunin G, et al. Antimicrobial treatment for ventilator-associated tracheobronchitis： a randomized, controlled, multicenter study. Crit Care. 2008；12(3)：R62 – reference: 396) Nakamura-Uchiyama F, Hiromatsu K, Ishiwata K, Sakamoto Y, Nawa Y.：The current status of parasitic diseases in Japan. Intern Med 2003；42：222―36. – reference: 38) Rello J, Gattarello S, Souto J,Sole-Violan J, Valles J, Peredo R, et al.：Community-acquired Legionella pneumonia in the intensive care unit：Impact on survival of combined antibiotic therapy. Med Intensiva. 2013；37：320―6. – reference: 14) Saito A, Kohno S, Matsushima T, Watanabe A, Oizumi K, Yamaguchi K, et al. Prospective multicenter study of the causative organisms of community-acquired pneumonia in adults in Japan. J Infect Chemother. 2006；12：63―9. – reference: 140) 谷鎮礼，冨岡洋海，金田俊彦，久保田未央，金子正博，藤井宏．Nursing home-acquired pneumonia 入院症例の検討―高齢者市中肺炎との比較―．日呼吸会誌 2009；47（5）：355―61 – reference: 256) Benator D, Bhattacharya M, Bozeman L, Burman W, Cantazaro A, Chaisson R, et al. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients： a randomised clinical trial. Lancet. 2002；360：528―34. – reference: 309) Burley CJ, Masterton RG, Lovell DP.： Indicators of bacterial infection in patients with acute exacerbation of chronic bronchitis for application in clinical trials of antibacterial drugs. J Infect. 2007；55(3)：226―32. – reference: 372) Donnelly BW, McMillan JA, Weiner LB.：Bacterial tracheitis： report of eight new cases and review. Rev Infect Dis. 1990；12：729―35. – reference: 325) Granizo JJ, Giménez MJ, Barberán J, Coronel P, Gimeno M, Aguilar L.： The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae： a pooled analysis of seven clinical trials. Clin Ther. 2006；28(12)：2061―9. – reference: 352) Roosevelt GE. Acute inflammatory upper airway obstruction (Croup, epiglottitis, laryngitis, and bacterial tracheitis）. In： Kliegman RM, Behrman RE, Jenson HB, Stanton BF, ed. Nelson Textbook of Pediatrics,19th ed. Saunders, Philadelphia, 2011,pp1445―50. – reference: 145) 比嘉太，斉藤厚．誤嚥性肺炎の起炎菌．Geriatr Med 1997；35：153―6 – reference: 205) 須藤扶佐代，石和田稔彦，星野直，深沢千絵，稲見由紀子，菱木はるか，他．小児Haemophilus influenzae気管支肺感染症に対するpiperacillin, tazobactam/piperacillinの臨床効果に関する検討．感染症誌． 2005；79：637―43. – reference: 383) Domínguez-Cherit G, Lapinsky SE, Macias AE, Espinosa-perez L, dela Torre A, Poblano-Morales M, et al：Critically ill patients with 2009 influenza A (H1N1) in Mexico. JAMA 2009；302：1880―7. – reference: 91) Trouillet JL, Chastre J, Vuagnat A, Joly-Guillou ML, Combaux D, Dombret MC, et al. Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am J Respir Crit Care Med 1998；157：531―9. – reference: 321) 高畑正裕，福田淑子，二口直子，杉浦陽子，久田晴美，水永真吾，他：Garenoxacin のinvitro 抗菌活性日化療誌．2007；55（S-1）：1―20. – reference: 227) 佐藤吉壮．2 章各種感染症と薬の選び方・使い方 新生児期 新生児感染症．小児科臨床ピクシス11．中山書店，東京，2009；p252―7. – reference: 143) Rosenthal VD, Rodrigues C, Álvarez-Moreno C, Madani N, Mitrev Z, Ye G, et al. Effectiveness of a multidimensional approach for prevention of ventilator-associated pneumonia in adult intensive care units from 14 developing countries of four continents： findings of the International Nosocomial Infection Control Consortium. Crit Care Med. 2012；40(12)：3121-8 – reference: 245) 小田切邦雄．小児Mycoplasma肺炎のX線学的研究．横浜医学．1979；30：113―22. – reference: 176) Kohno S, Izumikawa K, Yoshida M, Takesue Y, Oka S, Kamei K, et al. Adouble-blind comparative study of the safety and efficacy of caspofungin versus micafungin in the treatment of candidiasis and aspergillosis. Eur J Clin Microbiol Infect Dis. 2013；32(3)：387―97 – reference: 191) McIntosh K. Community-acquired pneumonia in children. N Engl J Med. 2002；346：429―3 – reference: 8) Helbig JH, Uldum SA, Lück PC, Harrison TG. Detection of Legionella pneumophila antigen in urine samples by the BinaxNOW immunochromatographic assay and comparison with both Binax Legionella Urinary Enzyme Immunoassay (EIA) and Biotest Legionella Urin Antigen EIA. J Med Microbiol. 2001；50：509―16. – reference: 71) Craven DE, Chroneou A. Nosocomial pneumonia. In： Mandell GL, Bennett JE, Dolin R, ed. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases, 7th edition, Churchill Livingstone Elsevier, Philadelphia, 2010. p3717―3724. – reference: 338) Keicho N and Kudo S.： Diffuse panbronchiolitis： role of macrolides in therapy. Am J Respir Med. 2002；1：119―31. – reference: 224) Yuan TM, Chen LH, Yu HM. Risk factors and outcomes for ventilator-associated pneumonia in neonatal intensive care unit patients. J Perinat Med. 2007；35：334―8. – reference: 264) Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America.(IDSA), September 1999, and the sections of this statement. Am J Respir Crit Care Med 2000；161：S221―47. – reference: 243) 小児呼吸器感染症診療ガイドライン作成委員会．胸膜炎・膿胸．小児呼吸器感染症診療ガイドライン2011 協和企画，東京，2011；p50―51 – reference: 322) Araki N, Yanagihara K, Matsukawa Y, Harada Y, Migiyama Y, Nagaoka K, et al.： Molecular characterization of quinolone-insensitive Streptococcus pneumoniae isolates from Japanese patients. J Infect Chemother. 2013；19(2)：356―9. – reference: 259) Curry FJ.：Prophylactic effect of isoniazid in young tuberculin reactors. N Engl J Med. 1967；277：562―7. – reference: 87) Nathwani D, Morgan M, Masterton RG, Dryden M, Cookson BD, French G, et al. Guidelines for UK practice for the diagnosis and management of methicillin-resistant Staphylococcus aureus (MRSA) infections presenting in the community. J Antimicrob Chemother 2008；61：976―94. – reference: 82) Dobbs T, Patel M, Waites KB, Moser SA, Stamm AM, Hoesley CJ. Nosocomial spread of Enterococcus faecium resistant to vancomycin and linezolid in a tertiary medical center. J Clin Microbiol. 2006；44：3368―70. – reference: 307) Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA.： Antibiotic therapy in exacerbation of chronic obstructive pulmonary disease. Ann Intern Med. 1987；106：196―204. – reference: 351) 日本呼吸器学会呼吸器感染症に関するガイドライン作成委員会.：第IX 章びまん性汎細気管支炎の急性増悪と持続感染．「呼吸器感染症に関するガイドライン」成人気道感染症診療の基本的考え方．東京，2003：p43―45. – reference: 276) Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al；ATS Mycobacterial Diseases Subcommittee；American Thoracic Society； Infectious Disease Society of America. An official ATS/IDSA statement： diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007；175：367―416. – reference: 375) Cherry JD, Nieves DJ. Bronchitis. In： Feigin RD, et al. (eds) Feigin and Cherry’s Textbook of Pediatric Infectious Diseases, 6th ed. Saunders, Philadelphia, 2009,pp269―72. – reference: 15) 東山康仁，渡辺彰，青木信樹，二木芳人，河野茂：慢性閉塞性肺疾患症例の急性増悪に対するニューキノロン系抗菌薬とβ―ラクタム系抗菌薬の有用性．日化療会誌．2009；56（1）：33―48. – reference: 28) Taba H, Kusano N. Spafloxacin resistance in clinical isolates of Streptococcus pneumoniae：involvement of multiple mutations in gyrA and parC genes. Antimicrob Agents Chemother 1998；42：2193―6. – reference: 155) 村谷哲郎．特集 泌尿器科感染症の今日的話題―難治性要因と対応― 2 尿路感染症分離菌における抗菌薬に対する耐性菌の状況と耐性化防止の方法について．化学療法の領域 2009；25：413―23 – reference: 349) Yamaya M, Azuma A, Tanaka H, Takizawa H, Chida K, Taguchi Y, et al.： Inhibitory effects of macrolide antibiotics on exacerbations and hospitalization in chronic obstructive pulmonary disease in Japan： a retrospective multicenter analysis. J Am Geriatr Soc. 2009；56：1358―60. – reference: 11) 日本呼吸器学会 呼吸感染症に関するガイドライン作成委員会 医療・介護関連肺炎診療ガイドライン2011．日本呼吸器学会 – reference: 137) Marie TJ. Epidemiology of community-acquired pneumonia in the elderly. Semin Respir Infect. 1990；5：260―8 – reference: 282) 吉田志緒美，鈴木克洋，露口一成，岩本朋忠，富田元久，岡田全司，他．リファンピシン耐性Mycobacterium kansasii におけるrpoB 変異の解明．結核．2006；81：475―9 – reference: 411) Hossack J, Ricketts P, Te HS, Hart J.：A case of adult hepatic toxocariasis. Nat Clin Pract Gastroenterol Hepatol. 2008；5：344―8. – reference: 382) Chartrand C, Leeflang M, Minion J, Brewer T, pai M. Accuracy of rapid influenza diagnostic tests. A metaanalysis. Annals of Internal Medicine 2012；156(7)：500―4 – reference: 260) Jenkins D, Davidson FF.：Isoniazid chemoprophylaxis of tuberculosis. Calif Med. 1972；116：1―5. – reference: 111) Norrby SR., Petermann W, Willcox PA, Vetter N, Salewski E. A comparative study of levofloxacin and ceftriaxone in the treatment of hospitalized patients with pneumonia. Scand J Infect Dis. 1998：30,397―404. – reference: 52) Masterton RG, Galloway A, French G, Street M, Armstrong J, Brown E, et al： Guidelines for the management of hospital-acquired pneumonia in the UK：report of the working party on hospital-acquired pneumonia of the British Society for Antimicrobial Chemotherapy. J Antimicrob Chemother 2008；62：5―34. – reference: 62) Blot F , Raynard B, Chachaty E, Tancrède H, Antoun S, Nitenberg G： Value of Gram stain examination of lower respiratory tract secretions for early diagnosis of nosocomial pneumonia. Am J Respir Crit Care Med 2000；162：1731―7. – reference: 47) Verduin CM, Hol C, Fleer A, van Dijk, van Belkum A. Moraxella catarrhalis：from emerging to established pathogen. Clin Microbiol Rev 2002；15：125―44. – reference: 186) Asberg A, Humar A, Rollag H, Jardine AG, Mouras H, Pescovitz MD, et al. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant. 2007；7：2106―13. – reference: 346) Anwar GA, Bourke SC, Afolabi G, Middleton P, Ward C, Rutherford RM.： Effects of long-term low-dose azithromycin in patients with non-CF bronchiectasis. Respir Med. 2008；102：1494―96. – reference: 409) Yoshikawa M, Koyama N, Hontsu S, Yamamoto Y, Mikasa K, Kimura H.：Lessons from eight cases of adult pulmonary toxocariasis： abridged republication. Respirology. 2011；16：1014―5. – reference: 138) Loeb M, McGeer A, McArthur M Walter S, Simor AE. Rsik factors for pneumonia and other lower respiratory tract infection in elderly residents of long term care facilities. Arch Intern Med. 1999；159(17)：2058―64 – reference: 20) Paterson DL, Ko WC, Von Gottbergn A, Mohapatra S, Casellas JM, Goossens H, et al. Antibiotic therapy for Klebsiella pneumoniae bacteremia： Implications of Production of Extended-Spectrum β-Lactamases. Clin infect Dis. 2004；30：31―7. – reference: 261) International Union Against Tuberculosis Committee on Prophylaxis.：Efficacy of various durations of isoniazid preventive therapy for tuberculosis： five years of follow-up in the IUAT trial. Bull World Health Organ. 1982；60：555―64. – reference: 329) Yang M, Dong BR, Lu J, Lin X, Wu HM.： Macrolides for diffuse panbronchiolitis. Cochrane Database Syst Rev. 2010；12；CD007716. – reference: 141) Teramoto S, Fukuchi Y, Sasaki H, Sato K, Sekizawa K, Matsuse T, et al. High incidence of aspiration pneumonia in community- and hospital-acquired pneumonia in hospitalized patients： a multi-center, prospective study in Japan. J Am Geriatr Soc. 2008；56(3)：577―9 – reference: 333) 山本正彦.：DPB に対するエリスロマイシンの治療効果―二重盲検による検討―．厚生省びまん性肺疾患調査研究班平成2 年度報告書．1991：p18―20. – reference: 161) Crouch BS, Wunderink RG, Jones CB, Jones CB, Leeper KV Jr. Ventilator-associated pneumonia due to Pseudomonas aeruginosa. Chest. 1996；109(4)：1019―29 – reference: 97) Shindo Y, Sato S, Maruyama E, Ohashi T, Ogawa M, Hashimoto N, et al. Health-care-associated pneumonia among hospitalizes patients in a Japanese community hospital. Chest. 2009；135(3)：633―40 – reference: 124) Livemore DM, Mushtaq S, Warner M. Selectivity of ertapnem for Psudomonas aeruginosa mutants cross-resisitant to other carbapenems. J Antimicrob Chemother. 2005；55(3)：306―11 – reference: 408) Akao N, Ohta N.：Toxocariasis in Japan. Parasitol. Int. 2007；56：87―93. – reference: 335) 大野彰二，杉山幸比古，北村諭.：慢性呼吸不全状態にあるびまん性汎細気管支炎に対するエリスロマイシン長期投与の効果．日胸疾会誌．1993；31：1251―6. – reference: 246) Pinkerton HJ. Lung. In Oldham KT, Colombani PM, Foglia RP, Skinner MA, eds. Principle and Practice of Pediatric surgery. Lippincott Williams ＆ Wilkins, Philadelphia, 2005；p.951―982. – reference: 171) Singh N, Limaye AP, Forrest G, Safdar N, Muñoz P, Pursell K, et al. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients： a prospective, multicenter, observational study. Transplantation. 2006；81(3)：320―6. – reference: 290) 厚生労働省健康局結核感染症課監修：「結核の統計2009 年版」．財団法人結核予防会，東京，2009 – reference: 327) Zervos M, Martinez FJ, Amsden GW, Rothermel CD, Treadway G.： Efficacy and safety of 3-day azithromycin versus 5-day moxifloxacin for the treatment of acute bacterial exacerbations of chronic bronchitis. Int J Antimicrob Agents. 2007；29(1)：56―61. – reference: 115) Vergis EN, Indorf A, File TM Jr, Phillips J, Bates J, Tan J, et al. Azithromycin vs cefuroxime plus erythromycin for empirical treatment of community-acquired pneumonia in hospitalized patients： a prospective, randomized, multicenter trial. Arch Intern Med. 2000；160(9)：1294―300 – reference: 275) Nightingale SD, Cameron DW, Gordin FM, Sullam PM, Cohn DL, Chaisson RE, et al.：Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS. N Engl J Med 1993；329：828―33. – reference: 405) Mokhlesi B, Shulzhenko O, Garimella PS, Kuma L, Monti C .：Pulmonary Strongyloidiasis： The Varied Clinical Presentations. Clin Pulm Med. 2004；11：6―13. – reference: 384) Ariano RE, Sitar DS, Zelenitsky SA, Zarychansk R, Pisipati A, Ahem S, et al： Enteric absorption and pharmaco-kinetics of oseltamivir in critically ill patients with pandemic (H1N1) influenza. CMAJ 2010；182：357―63. – reference: 364) Field CM, Connolly JH, Murtagh G, Slattery CM, Turkington EE.：Antibiotic treatment of epidemic bronchiolitis--a double-blind trial. Br Med J. 1966；1(5479)：83―5. – reference: 74) Chastre J：Antimicrobial treatment of hospital-acquired pneumonia. Infect Dis Clin N Am. 2003；17：727―37 – reference: 55) Chastre J, Fagon JY： Ventilator-associated pneumonia. Am J Respir Crit Care Med 2002；165：867―903. – reference: 96) The JRS Guidelines for the management of nursing and healthcare pneumonia. The committee for the JRS guidelines in management NHCAP. 2011 日本呼吸器学会「医療・介護関連肺炎（NHCAP）診療ガイドライ ン作成委員会」．医療・介護関連肺炎診療ガイドライン．日本呼吸器学会，東京，2011 – reference: 336) Fujii T, Kadota J, Kawakami K, Iida K, Shirai R, Kaseda M, et al.： Long term effect of erythromycin therapy in patients with chronic Pseudomonas aeruginosa infection. Thotrax. 1995；50：1246―52. – reference: 234) Boyanova L, Vladimir D, Gergova G, Dragomir Iotov, Petrov D, Osmanliev D,et al. Anaerobic microbiology in 198 cases of pleural empyema ： a Bulgarian study. Anaerobe. 2004；10：261―7. – reference: 10) Seki M, Watanabe A, Mikasa K, Kadota J, Kohno S. Revision of the severity rating and classification of hospital-acquired pneumonia in the Japanese Respiratory Society guidelines. Respirology 2008；13：880―5. – reference: 203) Clinical and Laboratory Standard Institute：Performance Standards for Antimicrobial Susceptibility Testing；18th Informational Supplement. 2008. Vol.28 – reference: 135) The JRS Guidelines for the Management of hospital-acquired pneumonia in adults. The committee for the JRS guidelines in management of respiratory infections. 2008； Tokyo, Japan 日本呼吸器学会「呼吸器感染症に関するガイドライン作成委員会」．成人院内肺炎診療ガイドライン．日本呼吸器学会，東京，2008 – reference: 263) Comstock GW.：How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? Int J Tuberc Lung Dis. 1999；3：847―50. – reference: 153) Kadowaki M, Demura Y, Mizuno S, Uesaka D, Ameshima S, Miyamori I, et al. Reappraisal of clindamycin IV monotherapy for treatment of mild-to-moderate aspiration pneumonia in elderly patients. Chest. 2005；127(4)：1276―82 – reference: 158) Karino F, Deguchi N, Kanda H, Ohe M, Kondo K, Tada M, et al. Evaluation of the efficacy and safety of biapenem against pneumonia in the elderly and a study on its pharmacokinetics. J Infect Chemother. 2013；19(1)：98―102 – reference: 241) Wozniak CJ, Paull DE, Moezzi JE, Scott RP, Anstadt MP, York VV, et al. Choice of first intervention is related to outcomes in the management of empyema；discussion 30―1. Ann Thorac Surg. 2009；87：1525―30. – reference: 242) Davies HE, Davies RJ, Davies CW. Management of pleural infection in adults：British Thoracic Society Pleural Disease Guideline 2010. Thorax. 2010；65 Suppl 2：ii41―53. – reference: 46) Yamamoto N, Fujita J, Shinzato T, Higa F, Tateyama M, Tohyama M, et al.：In vitro activities of sitafloxacin compared with several fluoroquinolones against Streptococcus anginosus and Streptococcus constellatus. Int J Antimicrob Agents 2006；27：171―3. – reference: 130) 三笠桂一，古西満，前田光一．経気管吸引法による呼吸器感染症における嫌気性菌の検討．日嫌気性菌感染症 2003；33： 52―60 – reference: 26) Lim WS, Baudouin SV, George RC, Hill AT, Jamieson C, Le Jeune I, BTS Guidelines for the Management of Community Acquired Pneumonia in Adults：2009 Update. Thorax. 2009；64 Suppl 3：1―55. – reference: 41) Mine Y, Nakasone I, Yamamoto Y, Utani A, Yamane N, Uezato H, et al. Dissemination of Panton-Valentine leukocidine positive metchicillin-resistant Staphylococcus aureus in Okinawa, Japan. J Dermatol 2013；40：34―8. – reference: 306) Tan T, Little P, Stokes T： Antibiotic prescribing for self limiting respiratory tract infections in primary care： summary of NICE guidance. BMJ. 2008；337：a437. – reference: 225) Katayama Y, Minami H, Enomoto M, Takano T, Hayashi S, Lee YK. Usefulness of Gram staining of tracheal aspirates in initial therapy for ventilator-associated pneumonia in extremely preterm neonates. J Perinatol. 2010；30：270―4. – reference: 75) Cunha BA. Nosocomial fever of unknown origin. Fever of unknown origin. Cunha BA, ed. Informa healthcare, NY, 2007. p101―108. – reference: 316) Grossman RF, Ambrusz ME, Fisher AC, Khashab MM, Kahn JB.： Levofloxacin 750mg QD for five days versus amoxicillin/clavulanate 875mg/125mg BID for ten days for treatment of acute bacterial exacerbation of chronic bronchitis： a post hoc analysis of data from severely ill patients. Clin Ther. 2006；28：1175―80 – reference: 136) 嚥下性肺疾患研究会．嚥下性肺疾患の診断と治療．ファイザー，東京，2003 – reference: 90) Fink MP, Snydman DR, Niederman MS, Leeper KV Jr, Johnson RH, Heard SO, et al. Treatment of severe pneumonia in hospitalized patients： results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group. Antimicrob Agents Chemother. 1994；38：547―57. – reference: 159) Brun-Buisson C, Sollet JP, Schweich H, Brière S, Petit C. Treatment of ventilator-associated pneumonia with piperacillin-tazobactam/amikacin versus ceftazidime/amikacin： a multicenter, randomized controlled trial. VAP Study Group. Clin Infect Dis. 1998；26(2)：346―54 – reference: 330) 工藤翔二，植竹健司，萩原弘一，平山雅清，許栄宏，木村仁，他.：びまん性汎細気管支炎にたいするエリスロマイシン少量長期投与の臨床効果に関する研究―4 年間の治療成績．日胸疾会誌．1987；25：632―42. – reference: 101) Kollef MH, Shorr A, Tabak YP, Gupta V, LiuL Z, Johannes RS. Epidemiology and outcomes of healthcare associated pneumonia：results from a large US database of culture-positive pneumonia. Chest. 2005；128：3854―62 – reference: 154) Hirakata Y, Matsuda J, Miyazaki Y, Kamihira S, Kawakami S, Miyazawa Y, et al. Regional variation in the prevalence of extended-spectrum β-lactamase-producing clinical isolates in the Asia-Pacific region (SENTRY 1998―2002). Diagn Microbiol Infect Dis. 2005；52：323―9 – reference: 279) 日本結核病学会非結核性抗酸菌症対策委員会，日本呼吸器学会感染症・結核学術部会．肺非結核性抗酸菌症化学療法に関する見解―2012年改訂．結核 2012；87：83―6. – reference: 394) Streng A, Grote V, Liese JG.：Severe influenza cases in paediatric intensive care units in Germany during the pre-pandemic seasons 2005 to 2008. BMC Infect Dis. 2011；11：233. – reference: 152) 金子明寛，山根伸夫，渡辺大介，水澤伸仁，松崎薫，長谷川美幸，他：誤嚥性肺炎の起炎菌として高頻度に分離される口腔内細菌の薬剤感受性．日化療会誌．2007；55：378―81 – reference: 61) Fartoukh M, Maître B, Honoré S, Cerf C, Zahar JR, Brun-Buisson C： Diagnosing pneumonia during mechanical ventilation：The clinical pulmonary infection score revisited. Am J Respir Crit Care Med 2003；168：173―9. – reference: 310) Sethi S, Murphy TF.： Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med. 2008； 359[22]：2355―65. – reference: 177) RegnardJ F, Icard P, Nicolosi M, Spagiarri L, Magdeleinat P, Jauffret B, et al. Aspergilloma： a series of 89 surgical cases. Ann Thorac Surg. 2000；69(3)：898―903. – reference: 341) 白井亮，阿部航，良永倫子，石松祐二，松原祐一，川上かおる，他.：びまん性汎細気管支炎に対するエリスロマイシン療法の中止可能症例の検討―投与中止例と投与継続例の比較―．感染症誌．1997；71：1155―61. – reference: 387) South East Asia Innfectious Disease Clinical Research Network：Effect of double dose oseltamivir on clinical and virological outcomes in children and adults admitted to hospital with severe influenza：double blindrandomised controlled trial. BMJ 2013；346：f3039 – reference: 4) Watanabe A. Goto H, Kohno S, Matsushima T, Abe S, Aoki N, et al. Nationwide survey on the 2005 Guidelines for the Management of Community-Acquired Adult Pneumonia：Validation of differentiation between bacterial pneumonia and atypical pneumonia. Respir Investig. 2012；50：23―32. – reference: 120) Labelle AJ, Arnold H, Reichley RM, Micek ST, Kollef MH. A comparison of culture-positive and culture-negative health-care-associated pneumonia. Chest. 2010；137(5)：1130―7 – reference: 50) 日本呼吸器学会 呼吸器感染症に関するガイドライン作成委員会．成人院内肺炎診療ガイドライン．日本呼吸器学会．2008．東京 – reference: 280) Medical Section of the American Lung Association.：Diagnosis and treatment of disease caused by nontuberculous mycobacteria. This official statement of the American Thoracic Society was approved by the Board of Directors, March 1997. Am J Respir Crit Care Med. 1997；156：S1―25. – reference: 199) Ubukata K. Problems associated with high prevalence of multidrug-resistant bacteria in patients with community-acquired infections. J Infect Chemother. 2003；9：285―91 – reference: 24) Pallares R, Liñares J, Vadillo M, Cabellos C, Manresa F, Viladrich PF, et al. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med 1995,333：474―80. – reference: 213) 小児呼吸器感染症診療ガイドライン作成委員会．基礎疾患のある肺炎 1．血液疾患．小児呼吸器感染症診療ガイドライン2011 協和企画，東京，2011；p52―55 – reference: 122) Teramoto S, Kawashima M, Komiya K, Shoji S. Health-care-associated pneumonia is primarily due to aspiration pneumonia. Chest. 2009；136(6)：1702―3 – reference: 337) Kudo S, Azuma A, Yamamoto M, Izumi T, Ando M.： Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. Am J Respir Crit Care Med. 1998；157：1829―32. – reference: 94) Álvarez-Lerma F, Grau S, Álvarez-Beltrán M： Levofloxacin in the treat-ment of ventilator-associated pneumonia. Clin Microbiol Infect. 2006；12 Suppl.3：81―92 – reference: 118) Fujisawa K, Chiba M, Tanaka M, Sato K. In vitro antibacterial activity of DX-619, a novel des-fluoro (6) quinolone. Antimicrob Agents Chemother. 2005；49(7),3040―5 – reference: 304) Hsu J, Santesso N, Mustafa R, Brozek J, Chen YL, Hopkins JP, et al.：Antivirals for treatment of influenza： a systematic review and meta-analysis of observational studies. Ann Intern Med. 2012；156：512―24. – reference: 197) Pönkä A, Sarna S. Differential diagnosis of viral, mycoplasmal and bacteraemic pneumococcal pneumonias on admission to hospital. Eur J Respir Dis. 1983；64：360―8. – reference: 83) Bonora MG, Solbiati M, Stepan E, Zorzi A, Luzzani A, Rosaria M, et al. Emergence of linezolid resistance in the vancomycin-resistant Enterococcus faecium multilocus sequence typing C1 epidemic lineage. J Clin Microbiol. 2006；44：1153―5. – reference: 27) Petitpretz P, Arvis P, Marel M, Moita J, Urueta J, CAP5 Moxifloxacin Study Group. Oral moxifloxacin vs high-dosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults. Chest 2001,119：185―95. – reference: 248) East African/British Medical Research Councils.： Controlled clinical trial of four short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Second report. Lancet. 1973；1：1331―8. – reference: 369) Al-Mutairi B, Kirk V.：Bacterial tracheitis in children：Approach to diagnosis and treatment. Paediatr Child Health. 2004；9：25―30. – reference: 238) Shohet I, Yellin A, Meyerovitch J, Rubinstein E. Pharmacokinetics and therapeutic efficacy of gentamicin in an experimental pleural empyema rabbit model. Antimicrob Agents Chemother. 1987；31：982―5. – reference: 226) 佐藤吉壮．小児感染症のすべてI 感染症の種類別に小児感染症を考える13 新生児感染症．化学療法の領域．2009；25 （Suppl.1）：985―94. – reference: 86) Rubinstein E, Cammarata S, Oliphant T, Wunderink RG, and the Linezolid Nosocomial Pneumonia Study Group. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia：a randomized, double-blind, multicenter study. Clin Infect Dis 2001；32：402―12. – reference: 123) Yacovlev SV, Strachounski LS, Woods GL, Adeyi B, McCarroll KA, Ginanni JA, et al. Ertapenem versus cefepime for initial empirical treatment of pneumonia acquired in skilled-care facilities or in hospitals outside the intensive care unit. Eur J Clin Microbiol Infect Dis. 2006；25(10)：633―41 – reference: 296) Gonzales R, Sande MA： Uncomplicated Acute Bronchitis. Ann Intern Med. 2000；133：981―91. – reference: 221) 小児呼吸器感染症診療ガイドライン作成委員会．基礎疾患のある肺炎 3．新生児．小児呼吸器感染症診療ガイドライン2011 協和企画，東京，2011；p58―62 – reference: 121) El-Solh AA, Akinnusi ME, Alfarah Z, Patel A. Effect of antibiotic guidelines on outcomes of hospitalized patients with nursing home-acquired pneumonia. J Am Geriatr Soc. 2009；57(6)：1030―5 – reference: 272) Wallace RJ Jr., Brown BA, Griffith DE, Girard WM, Murphy DT, Onyi GO, et al.：Initial clarithromycin monotherapy for Mycobacterium avium-intracellulare complex lung disease. Am J Respir Crit Care Med. 1994；149：1335―41. – reference: 413) 輸入熱帯病・寄生虫症に対する稀少疾病治療薬を用いた最適な治療法による医療対応の確立に関する研究班．寄生虫症薬物治療の手引き．熱帯病治療薬研究班． 東京，2010. – reference: 33) Okada T, Morozumi M, Tajima T, Hasegawa M, Sakata H, Ohnari S, et al. Rapid effectiveness of minocycline or doxycycline against macrolide-resistant Mycoplasma pneumoniae infection in a 2011 outbreak among Japanese children. Clin Infect Dis 2012；55：1642―9. – reference: 210) 黒崎知道，尾内一信．1 次医療機関における肺炎マイコプラズマのマクロライド耐性．IASR 2012；33：267―8. – reference: 314) Chuchalin A, Zakharova M, Dokic D, Tokić M, Marschall HP, Petri T.： Efficacy and safety of moxifloxacin in acute exacerbations of chronic bronchitis： a prospective, multicenter, observational study (AVANTI). BMC Pulm Med. 2013 23；13：5.doi：10.1186/1471-2466-13-5. – reference: 63) Chastre J, Fagon JY,Bornet-Lecso M, Calvat S, Dombret MC, alKhani R, et al. Evaluation of bronchoscopic techniques for the diagnosis of nosocomial pneumonia. Am J Respir Crit Care Med 1995；152：231―40. – reference: 410) Stürchler D, Schubarth P, Gualzata M, Gottstein B, Oettli A.：Thiabendazole vs. albendazole in treatment of toxocariasis： a clinical trial. Ann Trop Med Parasitol. 1989；83：473―8. – reference: 160) Jaccard C,T roillet N, Harbarth S, Zanetti G, Aymon D, Schneider R, et al. Prospective randomized comparison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis. Antimicrob Agents Chemother. 1998；42(11)：2966―72 – reference: 51) American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005；171：388―416. – reference: 318) Falagas ME, Avgeri SG, Matthaiou DK, Dimopoulos G, Siempos II.： Short-versus long-duration antimicrobial treatment for exacerbations of chronic bronchitis： a meta-analysis. J Antimicrob Chemother. 2008；62(3)：442―50. – reference: 286) Daley CL, Griffith DE.： Pulmonary disease caused by rapidly growing mycobacteria. Clin Chest Med. 2002；23：623―32. – reference: 2) Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al.：Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults. Clin Infect Dis. 2007；44：S27―72. – reference: 363) Mansbach JM, McAdam AJ, Clark S, Hain PD, Flood RG, Acholonu U, et al.： Prospective multicenter study of the viral etiology of bronchiolitis in the emergency department. Acad Emerg Med. 2008；15：111―8. – reference: 320) Adams SG, Melo J, Luther M, Anzueto A.： Antibiotics are associated with lower relapse rates in outpatients with acute exacerbations of COPD. Chest. 2000；117：1345―52. – reference: 54) Rello J, Paiva JA, Baraibar J, Barcenilla F, Bodi M, Castander D, et al： International conference for the development of consensus on the diagnosis and treatment of ventilator-associated pneumonia. Chest 2001；120：955―70. – reference: 215) Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer： 2010 update by The Infectious Diseases Society of America. Clin Infect Dis. 2011；52(4)：e56-e93. – reference: 323) Nakamura S, Yanagihara K, Morinaga Y, Izumikawa K, Seki M, Kakeya H, et al.： Comparative mutant prevention concentration and mutant selection window of sitafloxacin versus other quinolones using strains of Haemophilus influenzae with decreasing susceptibility to levofloxacin. Int J Antimicrob Agents. 2009；33(5)：489―90. – reference: 201) Sakata H, Toyonaga Y, Sato Y, Hanaki H, Nonoyama M, Oishi T, et al. Nationwide survey of the development of drug-resistance in the pediatric field： drug sensitivity of Haemophilus influenzae in Japan. J Infect Chemother. 2009；15：402―9. – reference: 295) Wenzel RP, Fowler AA 3rd.： Clinical practice. Acute bronchitis. N Engl J Med. 2006；355：2125―30. – reference: 178) Yamaguchi H, Ikemoto H, Watanabe K, Ito A, Hara K, Kohno S. Fluconazole Monotherapy for Cryptococcosis in Non-AIDS Patients. Eur J Clin. Microbiol Infect Dis.1996；15：787―92 – reference: 183) The National Institute of Health-University of California Expert Panel for Corticosteroids as Adjunctive Therapy for Pneumocystis Pneumonia. Consensus statement on the use of corticosteroids as adjunctive therapy for pneumocystis pneumonia in the acquired immunodeficiency syndrome. N Engl J Med. 1990；323：1500―4. – reference: 374) Liston SL, Gehrz RC, Siegel LG, Tilelli J.：Bacterial tracheitis. Am J Dis Child. 1983；137：764―7. – reference: 300) Rothstein E, Edwards K.：Health burden of pertussis in adolescents and adults. Pediatr Infect Dis J. 2005；24：S44―7. – reference: 389) Glezen WP. Influenza viruses. In： Feigin RD, Cherry J, Demmler-Harrison GJ, Kaplan SL, eds. Feigin and Cherry’s Textbook of Pediatric Infectious Diseases, 6th ed. Saunders, Philadelphia, 2009,pp2395―414. – reference: 198) 石和田稔彦，黒崎知道，鳥羽剛，太田文夫，斉藤能厚，玉井和人，他．小児肺炎の現況 胸部エックス線像の検討．日小児会誌． 1994；98：2012―6. – reference: 175) Kohno S, Izumikawa K, Ogawa K, Kurashima A, Okimoto N, Amitani R, et al. Intravenous micafungin versus voriconazole for chronic pulmonary aspergillosis： a multicenter trial in Japan. J Infect. 2010；61(5)：410―8. – reference: 378) Taylor B, Abbott GD, Kerr MM, Fergusson DM.： Amoxycillin and co-trimoxazole in presumed viral respiratory infections of childhood：placebo-controlled trial. Br Med J. 1977；2(6086)：552―4. – reference: 170) Caillot D, Bassaris H, McGeer A, Arthur C, Prentice HG, Seifert W, et al. Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS. Clin Infect Dis. 2001；33(8)：e83―90. – reference: 359) Rajapaksa S, Starr M.：Croup-assessment and management. Aust Fam Physician. 2010；39：280―2. – reference: 278) Subcommittee of the Joint Tuberculosis Committee of the British Thoracic Society.： Management of opportunist mycobacterial infections： Joint Tuberculosis Committee Guidelines 1999. Thorax. 2000；55：210―8. – reference: 360) Watts KD, Goodman DM. wheezing, bronchiolitis, and bronchitis. In： Kliegman RM, Behrman RE, Jenson HB, Stanton BF, ed. Nelson Textbook of Pediatrics, 19th ed. Saunders, Philadelphia, 2011,pp1456―60. – reference: 166) Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002；347(6)：408―15. – reference: 106) Oosterheert JJ, Bonten MJM, Hac E, Schneider MM, Hoepelman IM. How good is the evidence for the recommended empirical antimicrobial treatment of patients hospitalized because of community-acquired pneumonia? A systematic review. J Antimicrob chemother 2003；52(4)：555―63 – reference: 131) Brown RB, Iannini P, Gross P, Kunkel M. Impact of initial antibiotic choice on clinical outcomes in community-acquired pneumonia： analysis of a hospital claims-made database. Chest. 2003；123(5)：1503―11 – reference: 406) Fusco DN, Downs JA, Satlin MJ, Pahuja M, Ramos L, Barie PS, et al.：Non-oral treatment with ivermectin for disseminated strongyloidiasis. Am J Trop Med Hyg. 2010；83：879―83. – reference: 393) Gutierrez C, Nazar GA, Torres JP.：Otolaryngological complications in patients infected with the influenza A (H1N1) virus. Otolaryngol Head Neck Surg. 2012；146：478―82. – reference: 386) 一般社団法人日本感染症学会インフルエンザ委員会．一般社団法人日本感染症学会提言鳥インフルエンザ （H7N9）への対応【暫定】．http://www.kansensho.or.jp/influenza/pdf/1305_teigen.pdf – reference: 78) Gould FK, Brindle R, Chadwick PR, Fraise AP, Hill S, Nathwani D, et al. MRSA Working Party of the British Society for Antimicrobial Chemotherapy. Guidelines (2008) for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infectionsin the United Kingdom. J Antimicrob Chemother 2009；63：849―61 – reference: 207) 大嶋寛子，黒崎知道，石川信泰，上原すゞ子，新美仁男．Moraxella catarrhalisによる小児下気道感染症の臨床的検討（第2 報）―Moraxella catarrhalisのindirect pathogenecityについて―．日児誌．1998；102：131―4. – reference: 301) Tiwari T, Murphy TV, Moran J： Recommended antimicrobial agents for the treatment and postexposure prophylaxis of pertussis： 2005 CDC Guidelines. MMWR Recomm Rep. 2005；54 (RR-14)：1―16. – reference: 235) Ahmed RA, Marrie TJ, Huang JQ. Thoracic empyema in patients with community-acquired pneumonia. Am J Med. 2006；119： 877―83. – reference: 269) Wallace RJ Jr., Brown BA, Griffith DE, Girard WM, Murphy DT.：Clarithromycin regimens for pulmonary Mycobacterium avium complex. The first 50 patients. Am J Respir Crit Care Med. 1996；153：1766―72. – reference: 98) Maruyama T, Niederman MS, Kobayashi T, Kobayashi H, Takagi T, D’Alessandro-Gabazza CN, et al. A prospective comparison of nursing home-acquired pneumonia with healthcare-associated pneumonia in nonintubated elderly. Resp Med 2008；102：1287―1295 – reference: 168) Maertens J, Egerer G, Shin WS, Reichert D, Stek M, Chandwani S, et al. Caspofungin use in daily clinical practice for treatment of invasive aspergillosis： results of a prospective observational registry. BMC Infect Dis. 2010；10：182. doi： 10.1186/1471-2334-10-182. – reference: 398) Obara A,Nakamura-Uchiyama F, Hiromatsu K, Nawa Y. Paragonimiasis cases recently found among immigrants in Japan. Intern Med. 2004；43：388―92. – reference: 313) 斎藤厚，谷川原祐介，渡辺彰，青木信樹，二木芳人，河野茂，他：呼吸器感染症に対するsitafloxacin の一般臨床試験．日化療会誌．2008；56（S-1）：63―80. – reference: 77) Bush K,Jacoby GA： Updated functional classification of β-lactamases. Antimicrob Agents Chemother 2010；54： 969―76. – reference: 240) ThysJ P, Vanderhoeft P, Herchuelz A, Bergmann P, Yourassowsky E. Penetration of aminoglycosides in uninfected pleural exudates and in pleural empyemas. Chest. 1988；93：530―2. – reference: 67) Cunha BA： Pneumonia Essentials (3rd ed). Physician’s Press, 2010,Boston – reference: 293) 徳永修：平成21年度厚生労働科学研究研究費補助金新型インフルエンザ等新興・再興感染症研究事業「結核対策の評価と新たな診断・治療技術の開発・実用化に関する研究」（加藤班）分担研究「小児結核対策・医療の評価」報告書 – reference: 350) Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JAD Jr, Criner GJ, et al.： Azithromycin for prevention of exacerbations of COPD. New Engl J Med. 2011；365：689―98. – reference: 401) Tomita M, Ishinari H, Matsuzaki Y, Shibata K, Koga Y, Yamaguchi R, Mukae H, Masumoto H, Matsukura S, Maruyama H, Nawa Y. A case of chronic pleural empyema by Paragonimus westermani infection resistant to chemotherapy and cured by surgical decortication. Jpn j Parasitol. 1996；45：242―6. – reference: 368) Hall CB, Powell KR, Schnabel KC, Gala CL, Pincus PH.：Risk of secondary bacterial infection in infants hospitalized with respiratory syncytial viral infection. J Pediatr. 1988；113：266―71. – reference: 212) Foglia E, Meier MD, Elward A. Ventilator-associated pneumonia in neonatal and pediatric intensive care unit patients. Clin Microbiol Rev. 2007；20：409―25. – reference: 93) Peleg AY, Seifert H, Paterson DL： Acinetobacter baumannii： emergence of a successful pathogen. Clin Microbiol Rev. 2008；21：538―82. – reference: 180) Shoham S, Magill SS, Merz WG, Gonzalez C, Seibel N, Buchanan WL, et al. Primary treatment of zygomycosis with liposomal amphotericin B：analysis of 28 cases. Med Mycol. 2010；48(3)：511―7. – reference: 287) Cremades R, Santos A, Rodríguez JC, Garcia-Pachón E, Ruiz M, Royo G.：Mycobacterium abscessus from respiratory isolates： activities of drug combinations. J Infect Chemother. 2009；15：46―8. – reference: 253) Joint Tuberculosis Committee of the British Thoracic Society.：Chemotherapy and management of tuberculosis in the United Kingdom： recommendations 1998. Thorax. 1998；53(7)：536―48. – reference: 317) El Moussaoui R, Roede BM, Speelman P, Bresser P, Prins JM, Bossuyt PM.： Short-course antibiotic treatment in acute exacerbations of chronic bronchitis and COPD： a meta-analysis of double-blind studies. Thorax. 2008；63：415―22. – reference: 9) Marcos MA, Jiménez de Anta MT, de la Bellacasa JP, González J, Martínez E, et al. Rapid urinary antigen test for diagnosis of pneumococcal community-acquired pneumonia in adults. Eur Respir J. 2003；21： 209―14. – reference: 58) Celis R, Torres A, Gatell JM, Almela M, Rodríguez-Roisin R, Agustí-Vidal A： Nosocomial pneumonia： A multivariate analysis of risk and prognosis. Chest 1988；93：318―24. – reference: 399) Mukae H, Taniguchi H, Matsumoto N, Iiboshi H, Ashitani J, Matsukura S, Nawa Y.：Clinicoradiologic features of pleuropulmonary Paragonimus westermani on Kyusyu Island, Japan. Chest. 2001；120：514―20. – reference: 42) Schweizer ML, Furuno JP, Harris AD, Johnson JK, Shardell MD, McGregor JC, et al. Comparative effectiveness of nafcillin or cefazolin versus vancomycin in metchicillin susceptible Staphylococcus aureus bacteremia. BMC Infect Dis 2011；11：279. – reference: 66) Hayon J, Figliolini C, Combes A, Trouillet JL, Kassis N, Dombret MC, et al. Role of serial routine microbiologic culture results in the initial management of ventilator-associated pneumonia. Am J Respir Crit Care Med 2002；165：41―46. – reference: 172) Marr KA, Boeckh M, Carter RA, Kim HW, Corey L. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis. 2004； 39(6)：797―802. – reference: 13) Watanabe A, Yanagihara K, Matsumoto T, Kohno S, Aoki N, Oguri T, et al. Nationwide surveillance of bacterial respiratory pathogens conducted by the Surveillance Committee of Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Clinical Microbiology in 2009：general view of the pathogens’ antibacterial susceptibility. J Infect Chemother. 2012；18(5)：609―20 – reference: 195) 石和田稔彦，黒崎知道，島羽剛，新美仁男．小児肺炎の現況―第2報― 炎症反応，臨床症状，理学的所見 からの検討．感染症誌．1995；69：284―90. – reference: 302) Altunaiji S, Kukuruzovic R, Curtis N, Massie J.：Antibiotics for whooping cough (pertussis). Cochrane Database Syst Rev. 2005： CD004404,2005. – reference: 356) Klassen TP.：Croup. A current perspective. Pediatr Clin North Am. 1999；46：1167―78. – reference: 236) Maskell NA, Davies CW, Nunn AJ, Hedley EL, Gleeson FV, Miller R, et al. U. K. Controlled trial of intrapleural streptokinase for pleural infection. N Engl J Med. 2005；352：865―74. – reference: 357) Rihkanen H, Rönkkö E, Nieminen T, Komsi KL, Räty R, Saxen H, et al.：Respiratory viruses in laryngeal croup of young children. J Pediatr. 2008；152：661―5. – reference: 181) Spellberg B, Ibrahim AS, Chin-Hong PV, Kontoyiannis DP, Morris MI, Perfect JR, et al. The Deferasirox AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study：a randomized, double-blinded, placebo-controlled trial. J Antimicrob Chemother. 2012；67(3)： 715―22. – reference: 366) Kabir AR, Mollah AH, Anwar KS, Rahman AK, Amin R, Rahman ME.：Management of bronchiolitis without antibiotics：a multicentre randomized control trial in Bangladesh. Acta Paediatr. 2009；98：1593―9. – reference: 48) Kuriyama T, Williams DW, Yanagisawa M, Iwahara K, Shimizu C, Nakagawa K, et al. Antimicrobial susceptibility of 800 anaerobic isolates from patients with dentoalveolar infection to 13 oral antibiotics. Oral Microbiol Immunol 2007；22：285―8. – reference: 18) 国立感染症研究所 感染症情報センター：〈注目すべき感染症〉マイコプラズマ肺炎．IDWR. 2012；39：7―9. – reference: 147) Allewelt M, Schüler P, Bölcskei PL, Mauch H, Lode H. Ampicillin＋sulbactam vs clindamysin±cephalosporin for the treatment of aspiration pneumonia and primary lung abscess. Clin Microbiol Infect. 2004,10：163―70 – reference: 385) Hsu J, Santesso N, Mustafa R, Brozek J, Chen YL, Hopkins JP. Antivials for treatment of influenza. A systemic review and meta-analysis of observation studies. Annals of Internal Medicine 2013；156(7)：512―24 – reference: 367) Tahan F, Ozcan A, Koc N.：Clarithromycin in the treatment of RSV bronchiolitis：a double-blind, randomised, placebo-controlled trial. Eur Respir J. 2007；29：91―7. – reference: 104) von Baum H, Welte T, Marre R, Suttorp N, Ewig S, CAPNETZ study group. Community-acquired pneumonia through Enterobacteriaceae and Pseudomonas aeruginosa： Diagnosis, incidence and predictors. Eur Resp J. 2010；35：598―605 – reference: 119) Hedlund J, Ortqvist A, Ahlqvist T, Augustinsson A, Beckman H, Blanck C, et al. Management of patients with community-acquired pneumonia treated in hospital in Sweden. Scand J Infect Dis. 2002：34(12),887―92 – reference: 56) Singh N, Rogers P, Atwood CW, Wagener MM, Yu VL： Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription. Am J Respir Crit Cre Med 2000；162：505―11. – reference: 89) Fowler VG Jr, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. New Eng J Med 2006；355：653―65. – reference: 30) Kuroda H, Yano H, Hirakata Y, Arai K, Endo S, Kanamori H, et al.：Molecular characteristics of extended-spectrum β-lactamase-producing Escherichia coliin Japan：emergence of CTX-M-15-producing E.coli ST131. Diagn Microbiol Infect Dis 2012；74：201―3. – reference: 299) 古西満，澤木政好，三笠桂一，坂本正洋，前田光一，竹内章治，他：細菌性急性気管支炎の臨床的検討．感染症誌．1993；67： 452―8. – reference: 298) Braman SS.： Chronic cough due to acute bronchitis： ACCP evidence-based clinical practice guidelines. Chest. 2006；129 (Suppl 1).；95S―103S. – reference: 92) Munoz-Price LS, Weinstein RA： Acinetobacter infection. New Eng J Med. 2008；358：1271―81. – reference: 157) Brtlett JG. Anaerobic bacterial infection of the lung. Anaelobe. 2012；18：235―9 – reference: 216) 三澤眞人．正岡 徹編，血液疾患治療中の支持療法．医療ジャーナル社，大阪．2006：p.147―57. – reference: 355) Segal AO, Crighton EJ, Moineddin R, Mamdani M, Upshur RE.： Croup hospitalizations in Ontario： a 14-year time-series analysis. Pediatrics. 2005；116：51―5. – reference: 72) O’Neal PV, BrownN , Munro C：Physiologic factors contributing to a transition in oral immunity among mechanically ventilated adults. Biol Res Nurs 2002；3：1329. – reference: 328) 中田紘一郎，田口善夫，工藤翔二．：DPB の治療ガイドライン最終報告．厚生科学研究特定疾患研究対策事業びまん性肺疾患研究班 平成11 年度研究報告書．2000：p111. – reference: 324) Masterton RG, Burley CJ.： Randomized, double-blind study comparing 5- and 7-day regimens of oral levofloxacin in patients with acute exacerbation of chronic bronchitis. IInt J Antimicrob Agents. 2001；18：503―12. – reference: 128) 福山一，石田直，橘洋正，伊賀知也，仲川宏昭，伊藤明広，他．在宅介護寝たきり肺炎の臨床的検討．日呼吸会誌 2010；48（12）：906―11 – reference: 258) Ferebee SH.：Controlled chemoprophylaxis trials in tuberculosis. A general review. Bibl Tuberc. 1970；26：28―106. – reference: 292) Mori T. Usefulness of interferon-gamma release assays for diagnosing TB infection and problems with these assays. J Infect Chemother. 2009；15：143―55. – reference: 222) Jeong IS, Jeong JS, Choi EO. Nosocomial infection in a newborn intensive care unit (NICU), South Korea. BMC Infectious Diseases. 2006；6：103. – reference: 23) Clinical Laboratory Standard Institute. Performance standards for antimicrobial susceptibility testing； Twenty-third informational supplement. CLSI. 2013；M100-S23 – reference: 81) Kainer MA, Devasia RA, Jones TF, Simmons BP, Melton K, Chow S, et al. Response to emerging infection leading to outbreak ofl inezolid-resistant enterococci. Emerg Infect Dis. 2007；13：1024―30. – reference: 162) Matsushima A, Tasaki O, Shimizu K, Tomono K, Ogura H, Shimazu T, et al. Preemptive antibiotic treatment based on gram staining reduced the incidence of ARDS in mechanically ventilated patients. J Trauma. 2008；65(2),309―15 – reference: 192) 黒崎知道，石和田稔彦．第5回小児呼吸器セミナー．胸部X線写真を見直す：肺炎を中心として 3起炎病原体別からみた小児肺炎．日小呼誌．1998；9：124―34. – reference: 344) Nakamura H, Fujishima S, Inoue T, Ohkubo Y, Soejima K, Waki Y, et al.： Clinical and immunoregulatory effects of roxithromycin therapy for chronic respiratory tract infection. Eur respir J. 1999；13：1371―9. – reference: 331) 山本正彦，近藤有好，田村昌士，泉孝英，伊奈康孝，野田正治.：びまん性汎細気管支炎に対するエリスロマイシンおよびニューキノロン系薬剤の長期投与の検討―全国集計の検討―．日胸疾会誌．1990；28：1305―13. – reference: 334) Akira M, Higashihara T, Sakatani M, Hara H.： Diffuse panbronchiolitis： follow-up CT examination. Radiology. 1993；189：559―62. – reference: 142) Ewig S, Welte T, Chastre J, Torres A. Rethinking the concepts of community-acquired and health-care associated pneumonia. Lance Infect Dis. 2010；10(4)：279―87 – reference: 188) Ljungman P, Engelhard D, Link H, Biron P, Brandt L, Brunet S, et al. Treatment of interstitial pneumonitis due to cytomegalovirus with ganciclovir and intravenous immune globulin： experience of European Bone Marrow Transplant Group. Clin Infect Dis. 1992；14(4)：831―5. – reference: 169) Denning DW, Marr KA, Lau WM, Facklam DP, Ratanatharathorn V, Becker C, et al. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect. 2006；53(5)：337―49. – reference: 21) Mandell GL, Bennett JE, Dolin R, ed. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases, 7th edition, Churchill Livingstone Elsevier, Philadelphia, 2010. – reference: 174) Meletiadis J, Petraitis V, Petraitiene R, Lin P, Stergiopoulou T, Kelaher AM, et al. Triazole-polyene antagonism in experimental invasive pulmonary aspergillosis： in vitro and in vivo correlation. J Infect Dis. 2006；194(7)：1008―18. – reference: 285) Brown-Elliott BA, Wallace RJ Jr.：Clinical and taxonomic status of pathogenic nonpigmented or late-pigmenting rapidly growing mycobacteria. Clin Microbiol Rev. 2002；15(4)：716―46. – reference: 70) Marik PE, Careau P. The role of anaerobes in patients with ventilator-associated pneumonia and aspiration pneumonia： A prospective study. Chest. 1999；115：175―83. – reference: 358) Zoorob R, Sidani M, Murray J.：Croup：an overview. Am Fam Physician 2011；83：1067―73. – reference: 381) Centersof Disease Prevention (CDC)：Update：drug susceptibility of swine-origin influenza A (H1N1) viruses, April 2009. MMWR Morb Mortal Wkly Rep 2009；58(16)：433―5 – reference: 126) 日本化学療法学会，日本嫌気性菌感染症研究会．嫌気性菌感染症診断・治療ガイドライン2007 協和企画， 東京，2007 – reference: 289) Jarand J, Levin A, Zhang L, Huitt G, Mitchell JD, Daley CL.：Clinical and microbiologic outcomes in patients receiving treatment for Mycobacterium abscessus pulmonary disease. Clin Infect Dis. 2011；52：565―71. – reference: 400) Uchiyama F, Ishiwata K, Nawa Y.：Efficacy of chemotherapy of paragonimiasis in southern Kyushu, Japan. The 5th Asian-Pacific Congress for Parasitic Zoonosis. Chiba, 1998. – reference: 3) 日本呼吸器学会呼吸器感染症に関するガイドライン作成委員会：成人市中肺炎診療ガイドライン，日本呼吸器学会，東京，2007 – reference: 343) 門田淳一，崎戸修，河野茂，阿部航，白井亮，川上かおる，他.：慢性下気道感染症に対するロキシスロマイシン長期治療―臨床効果とサイトカインにおよぼす影響―．感染症誌．1994；68：27―33. – reference: 284) Griffith DE, Girard WM, Wallace RJ Jr.：Clinical features of pulmonary disease caused by rapidly growing mycobacteria. Ananalysis of 154 patients. Am Rev Respir Dis. 1993；147：1271―8. – reference: 129) Snydman DR, Jacobus NV, McDermott LA, Ruthazer R, Goldstein EJ, Finegold SM, et al. National survey on the susceptibility of Bacteroides fragilis group： report and analysis of trends for 1997―2000. Clin Infect Dis. 2002；35 Suppl 1：S126―34 – reference: 365) Kneyber MC, van Woensel JB, Uijtendaal E, Uiterwaal CS, Kimpen JL.：Azithromycin does not improve disease course in hospitalized infants with respiratory syncytial virus (RSV) lower respiratory tract disease：a randomized equivalence trial. Pediatr Pulmonol. 2008；43：142―9. – reference: 1) Donowitz GR. Acute pneumonia. In： Mandell GL, Bennett JE, Dolin R, ed. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases, 7th edition, Churchill Livingstone Elsevier, Philadelphia, 2010.p.891―916. – reference: 79) Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, et al. Clinicl practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011；52：1―38. – reference: 257) Combs DL, O’Brien RJ, Geiter LJ.：USPHS Tuberculosis Short-Course Chemotherapy Trial 21：effectiveness, toxicity, and acceptability. The report of final results. Ann Intern Med. 1990；112：397―406. – reference: 392) Wieching A, Benser J, Kohlhauser-Vollmuth C, Weissbrich B, Streng A, Liese JG.：Clinical characteristics of pediatric hospitalizations associated with 2009 pandemic influenza A (H1N1) in Northern Bavaria, Germany. BMC Res Notes. 2012；5：304. – reference: 196) 黒崎知道．「小児肺炎診療ガイドライン」に関する基礎的検討 治療の選択．日小誌．2003；14：198―204. – reference: 315) Starakis I, Gogos CA, Bassaris H.： Five-day moxifloxacin therapy compared with 7-day co-amoxiclav therapy for the treatment of acute exacerbation of chronic bronchitis. Int J Antimicrob Agents. 2004；23(2)：129―37. – reference: 361) Welliver RC. Bronchiolitis. In： Feigin RD, et al. (eds) Feigin and Cherry’s Textbook of Pediatric Infectious Diseases, 6th ed. Saunders, 2009,pp138―46. – reference: 395) Randolph AG, Vaughn F, Sullivan R, Rubinson L, Thompson BT, Yoon G, et al.：Critically ill children during the 2009―2010 influenza pandemic in the United States. Pediatrics. 2011；128：e1450―8. – reference: 214) 小児呼吸器感染症診療ガイドライン作成委員会．基礎疾患のある肺炎 2．免疫不全．小児呼吸器感染症診療ガイドライン2011 協和企画，東京，2011；p55―58 – reference: 99) Seki M, Hashiguchi K, Tanaka A, Kosai K, Kakugawa T, Awaya Y, et al. Characteristics and diseases everity of healthcare-associated pneumonia among patients in a hospital in Kitakyushu, Japan. J Infect Chemother. 2010；17(3)：363―9 – reference: 64) Fagon JY, Chastre J, Wolff M, Gervais C,Parer-Aubas S, Stéphan F, et al. Invasive and noninvasive strategies for management of suspected ventilator-associated pneumonia：a randomized trial. Ann Intern Med 2000；132：621―30. – reference: 49) Arancibia F, Bauer TT, Eqig S, Mensa J, Gonzalez J, Niederman MS, et al.：Community-acquired pneumonia due to gram-negative bacteria and Pseudomonas aeruginosa：incidence, risk, and prognosis. Arch Inter Med 2002；162：1849―58. – reference: 84) Funke G, von Graevenitz A, Clarridge III JE, Bernard KA： Clinical microbiology of Coryneform bacteria. Clin Microbiol Rev 1997； 10：125―59. |
| SSID | ssib000940252 ssib008799519 ssib058493432 ssib000959785 ssib020873179 ssib028667260 ssib002821772 ssj0000816464 ssib003038878 ssib002670505 ssib050995440 |
| Score | 2.0163035 |
| SourceID | jstage |
| SourceType | Publisher |
| StartPage | 1 |
| Title | JAID/JSC 感染症治療ガイドライン ―呼吸器感染症 |
| URI | https://www.jstage.jst.go.jp/article/kansenshogakuzasshi/88/1/88_1/_article/-char/ja |
| Volume | 88 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| ispartofPNX | 感染症学雑誌, 2014/01/20, Vol.88(1), pp.1-109 |
| journalDatabaseRights | – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 1884-569X dateEnd: 20141231 omitProxy: true ssIdentifier: ssj0000816464 issn: 0387-5911 databaseCode: KQ8 dateStart: 19700101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrR1Na9VAMNQK4kUUFb95gnsqabObr5mbm_dSakVBbKG3R_KSZ32FVrS99CStIN4UEempFw8KnvQi6I8RH23_hjObvCRqLbUIYRkmk9nsTHZnZrM7a1k30pTsshMk1L-dnu31-rmdZLlrk64lp2dLMnPYxJ27wcy8N7vgL4wd-95YtbS2mk721vfdV3IUrRKO9Mq7ZP9BsxVTQhBM-qWSNEzloXQ8q291-Izl--0JEQcCPIHTDFCJrohDgaGgYJ8wkRJRZDAoQInY5VK3R4BnALqwBDT-fityJ0YLI3wR-wKliNoGcEQEBkCh4YD3aPrBB76uL3RH6EDEKDDiimIQWguoJnTNnY5AZZ5uc7WqEEFErjG10-PWQlTTh9xY7TBviLnCkp7aon9lCyKaZoCFULL1GKVjA4AAp6YvEFjzL9lqaaTcpC9nViSvxrGVU_WFiopbCWCUErLYo9gINRLaNS1zjeAJr-kqXp7o_JEI2ocTqcdaQ90Y_zntsY-lLcoL-wTg2X5gTh-uDBjAHx21sEay4dZIk4ViP4vp8xrTpYR_ZTxZXHmQLK2tU9y2-JB626Ss3YRq8Wb5uXf3eaQL0JVFMaLizYPdAUUwxxXZXT5c5fa9RgCAHjndDQcbKcBtZFNSQchHLTYnCGQYNhPeuWQla37A-Q3rBIWKEK6s_0MrCIJQ1RMC5C2j79XZjsgbx2qntfHlgPPvFTnoSm2csK6P5Db1N6mROzug4G60MNT4qnOnrVNlkNnShXDOWGOD5Kx1k0eLKRorWrvPtne3X--9fb776eve1sZw4-Nw491w88Vw84MBPrd-PH2z8-rbzssvO1vvK-pz1vx0PNeescvzU-wBOfI0_GIoEVOVSxVgjwI38DPZc3LIMgyRXFNIEs5d5fS9VPVV0PczBM4Op9KegyDd89b48spyfsFq5WE_y9xewOc9eH0IQOVhSrECiTOlIMC_aHWKBncfFUlyukf6Si79HzaXrZN1f75ija8-XsuvUuywml4zn99PBsTh6w |
| linkProvider | Colorado Alliance of Research Libraries |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=JAID%2FJSC+%E6%84%9F%E6%9F%93%E7%97%87%E6%B2%BB%E7%99%82%E3%82%AC%E3%82%A4%E3%83%89%E3%83%A9%E3%82%A4%E3%83%B3+%E2%80%95%E5%91%BC%E5%90%B8%E5%99%A8%E6%84%9F%E6%9F%93%E7%97%87&rft.jtitle=%E6%84%9F%E6%9F%93%E7%97%87%E5%AD%A6%E9%9B%91%E8%AA%8C&rft.au=%E9%9D%92%E6%9C%A8%2C+%E6%B4%8B%E4%BB%8B&rft.au=%E7%AC%A0%E5%8E%9F%2C+%E6%95%AC&rft.au=%E9%98%BF%E9%83%A8%2C+%E4%BF%AE%E4%B8%80&rft.au=%E4%B8%89%E7%AC%A0%2C+%E6%A1%82%E4%B8%80&rft.date=2014-01-20&rft.pub=%E4%B8%80%E8%88%AC%E7%A4%BE%E5%9B%A3%E6%B3%95%E4%BA%BA+%E6%97%A5%E6%9C%AC%E6%84%9F%E6%9F%93%E7%97%87%E5%AD%A6%E4%BC%9A&rft.issn=0387-5911&rft.eissn=1884-569X&rft.volume=88&rft.issue=1&rft.spage=1&rft.epage=109&rft_id=info:doi/10.11150%2Fkansenshogakuzasshi.88.1&rft.externalDocID=article_kansenshogakuzasshi_88_1_88_1_article_char_ja |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0387-5911&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0387-5911&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0387-5911&client=summon |